Philip Morris International (PM) 10-K risk factor changes: FY2025 vs FY2024
The 2025-12-31 10-K against the 2024-12-31 one, compared heading by heading and sentence by sentence.
Item 1A81 rewritten36 added80 removed166 unchanged
All filing items1,524 rewritten656 added1,069 removed1,939 unchanged
Summary
counted, not written
- Item 1A lists 32 risk factor headings: 4 new, 5 reworded and 23 unchanged since FY2024. 5 headings from FY2024 no longer appear.
- Sentence by sentence, 656 added, 1,069 removed, 1,524 rewritten and 1,939 unchanged across 15 items that differ.
New Item 1A headings (4)
- The success of our business in the United States is dependent on an evolving legal and regulatory framework.
- Risks related to the natural environment and related legal or regulatory developments may have a negative impact on our business and results of operations.
- Our or our business partners’ failure or inability to adhere to privacy, data, artificial intelligence and information security laws could result in reputational harm, legal liability, and adversely affect our operating results.AI
- We increasingly use artificial intelligence-based solutions in our business, which could result in reputational harm, legal liability, and adversely affect our operating results.AI
Removed Item 1A headings (5)
- The effects of climate change, other environmental issues, and related legal or regulatory responses may have a negative impact on our business and results of operations.
- We face intense competition, and our failure to compete effectively could have a material adverse effect on our profitability and results of operations.
- We may be unable to expand our brand portfolio through acquisitions or the development of strategic business relationships, and the intended benefits from our investments may not materialize.
- Our or our business partners’ failure or inability to adhere to privacy, data, artificial intelligence and information security laws could result in business disruption, loss of reputation and consumer trust, litigation, regulatory action including significant fines or penalties, financial impact, and loss of revenue, assets or personal, confidential, or sensitive data.
- Accounting adjustments related to acquisitions could adversely affect our financial results.
Reworded Item 1A headings (5)
- We may be unsuccessful in our
[removed: attempts][added: efforts] to introduce, commercialize, and grow smoke-free products in existing and new markets, and regulators may prohibit or significantly restrict the commercialization of these products or the communication of scientifically substantiated information and claims. - Our business faces significant governmental
[removed: action][added: actions] aimed at increasing regulatory requirements with the goal of reducing or preventing the use of tobacco or nicotine-containing products. - Government mandated prices, production control programs, and shifts in crops driven by economic conditions may increase the cost or reduce the quality of
[removed: the]tobacco and other agricultural products used to manufacture our products. - A prolonged disruption of
[removed: our production]facilities [added: used to produce our products] could have a material adverse effect on our business, financial condition and results of operations. - Litigation related to tobacco
[removed: products]and nicotine products could substantially reduce our profitability and could severely impair our liquidity.
A heading is new when no FY2024 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
23 items, with every count and a link to each item that changed
Underlined words on a shaded ground are new in FY2025; struck-through words were in FY2024. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. Risk Factors.
81 rewritten, 36 added, 80 removed, 166 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
[added: Consequently, you] should not consider the following to be a complete discussion of all potential risks or uncertainties.
We may be unsuccessful in our [removed: attempts] [added: efforts] to introduce, commercialize, and grow smoke-free products in existing and new markets, and regulators may prohibit or significantly restrict the commercialization of these products or the communication of scientifically substantiated information and claims.
If [removed: we do not succeed, but others do,] [added: other market participants are more successful in these efforts] or if [removed: heat-not-burn products] [added: SFP categories where we hold a competitive advantage] are inequitably regulated compared to [added: cigarettes or] other SFP categories without regard to the totality of the scientific evidence available for such products, we may be at a competitive disadvantage.
[removed: In addition, actions of some market participants, such as the inappropriate] marketing of e-vapor products to youth, as well as alleged health consequences associated with the use of certain [removed: e-vapor products,] [added: SFPs,] may unfavorably impact public opinion and/or mischaracterize the health consequences of [removed: all e-vapor products or other] [added: our] SFPs to consumers, regulators and policy makers without regard to the totality of scientific evidence available for specific products.
This may impede our efforts to advocate for the development [added: and maintenance] of science-based regulatory frameworks for the development and commercialization of SFPs.
We cannot predict the extent to which regulators will permit [added: — or continue to permit —] the sale and/or marketing of [added: SFPs and regulatory restrictions have, and could further limit, the commercialization of our] SFPs.
[removed: The report concludes] [added: A significant factor influencing these developments are reports issued] by [removed: making] [added: the World Health Organization (the "WHO”) and Framework Convention on Tobacco Control (the "FCTC"), and related proposals, which make] a number of policy recommendations on [removed: HTPs and ENDS] [added: SFPs] that, if implemented, could restrict both the availability of these products and the access to accurate information about them.
[removed: Reports issued by the WHO] [added: These reports] and [removed: other FCTC guidelines or recommendations] [added: proposals] are not binding on the WHO Member States or on parties to the FCTC, and so it is not possible to predict the extent to which any [added: of the reports or] proposals [removed: it adopts will be implemented.][added: are implemented into regulations by Member States.]
However, [removed: the WHO proposals] [added: these proposed guidance documents] could [added: ultimately] lead to restrictions on the availability of certain of our SFPs [removed: and] [added: or] access to accurate information about them in one or more of our [added: current or future] markets, which could have a material adverse effect on our [added: financial] results [removed: of operations.][added: and growth prospects.]
Additionally, any claims, regardless of merit, challenging our research and clinical data available to date, may impact the development [added: and maintenance] of science-based regulatory frameworks for the commercialization of the SFP category and the commercialization of the SFP category in general.
We [added: also] put significant effort to restrict access of our products from [removed: non-smokers and youth.][added: underage persons.]
[added: If there is significant usage, whether actual or perceived, of our] products or competitive products among youth or [removed: non-smokers,] [added: non-nicotine users,] even in situations over which we have no control, our reputation and credibility may suffer, the regulatory approach to our products may become more restrictive, and our efforts to advocate for the development of science-based regulatory frameworks for the development and commercialization of SFPs may be significantly impacted.
The FDA’s premarket tobacco product and modified risk tobacco product authorizations of two versions of our *IQOS* product as well as the premarket tobacco authorizations of 20 varieties of *ZYN* [added: nicotine] pouches are subject to strict marketing, reporting and other requirements.
Although we have received these authorizations from the FDA, there is no guarantee that the products will remain authorized for sale in the [removed: U.S.,] [added: United States,] or that new versions of *IQOS* or other *ZYN* products will receive [removed: necessary] authorizations, particularly if there is a significant uptake in youth or [removed: non-smoker] [added: non-nicotine user] initiation.
Our SFPs [removed: are novel products] [added: compete] in [removed: a] relatively new [removed: category,] [added: categories,] and the pace at which adult smokers adopt them may vary, depending on the competitive, regulatory, fiscal and cultural environment, and other factors in a specific market.
To date, we have been largely successful in demonstrating to regulators that our SFPs are not cigarettes due to the absence of combustion, and accordingly they are [removed: generally] [added: frequently] taxed either as a separate category or as other tobacco products, which typically yields more favorable tax rates than cigarettes.
If we [removed: cease to be] [added: are not] successful in [removed: these efforts,] [added: our efforts to maintain differentiation,] SFP unit margins may be materially adversely affected, which in turn may have a material adverse effect on our results of operations, revenues, cash flows, and profitability.
These factors and their potential consequences are discussed more fully below and in Item 7, [removed: *Business Environment*.][added: Business Environment.]
[removed: A continuous] [added: The] decline in the consumption of cigarettes could have a material adverse effect on our revenues, cash flows and profitability, which in turn may have a material adverse effect on our ability to fund our smoke-free transformation.
Tax regimes, including excise taxes, sales taxes and import duties, can disproportionately affect the retail price of cigarettes versus other combustible tobacco products, or disproportionately affect the relative retail price of our cigarette brands versus cigarette brands [removed: manufactured by certain of our competitors.]
Our business faces significant governmental [removed: action] [added: actions] aimed at increasing regulatory requirements with the goal of reducing or preventing the use of tobacco or nicotine-containing products.
Governmental actions, combined with the diminishing social acceptance of smoking and private actions to restrict smoking, have resulted in reduced industry volumes for our [added: combustible] products in many of our markets, and we expect that such factors will continue to reduce [added: combustible] consumption levels and will increase down-trading and the risk of counterfeiting, contraband, illicit trade and cross-border purchases.
Regulatory initiatives that have been [added: contemplated,] proposed, [removed: introduced] [added: introduced,] or enacted by governmental authorities in various jurisdictions include:
| • | | | generation sales bans, under which the sale of certain tobacco or nicotine-containing products to people born after a certain year would be prohibited; [added: Classification of the product as food such that any nicotine amounts beyond de minimis content de facto bans the nicotine product from the market] | | |
| • | | | disclosure, restrictions, or bans of tobacco [added: and nicotine-containing] product ingredients, [added: components or other product features,] including bans on the flavors of certain tobacco and nicotine-containing [removed: products;] [added: products, and restrictions on certain device features;] | | |
| • | | | increased restrictions on smoking and use of tobacco and nicotine-containing products in public [removed: and work places and, in some instances, in] [added: or] private [removed: places and] [added: spaces, both indoors or] outdoors; | | |
More specifically, requirements that lead to a commoditization of tobacco products or impede adult consumers' ability to [added: access and] convert to our SFPs, as well as any significant increase in the cost of complying with new regulatory [removed: requirements] [added: requirements,] could have a material adverse effect on our financial [removed: results.][added: results and growth prospects.]
Changes in the tax laws of foreign jurisdictions could arise as a result of the base erosion and profit shifting project undertaken by the Organisation for Economic Co-operation and Development (the "OECD"), which [removed: recommended changes to numerous long-standing tax principles, and] could have a material adverse impact on our effective tax rate thereby reducing our net earnings.
[added: Such changes, as well as changes in taxing] jurisdictions’ administrative interpretations, decisions, policies, or positions, could also have a material adverse impact on our effective tax rate thereby reducing our net earnings.
[removed: Because we] [added: We] are a U.S. holding [removed: company, our] [added: company whose] most significant source of funds is distributions from our non-U.S. subsidiaries.
Our financial performance, [added: our] credit ratings, interest rates, the stability of financial institutions with which we partner, geopolitical or national developments, the stability and liquidity of the credit markets and the state of the global economy could affect the availability and cost of financing.
We could decide - or laws, regulations, or [removed: judicial] administrative action could require us - to recall products due to the failure, or alleged failure, to meet quality or safety standards or specifications, suspected or confirmed and deliberate or unintentional product contamination, manufacturing defects, or other product safety concerns, adulteration, misbranding or tampering.
A product recall or a product liability or other claim (even if unsuccessful or without merit) could generate negative publicity about us and our products, and our [removed: Company’s] reputation or that of our brands may be adversely affected.
[removed: Additionally, we] [added: We also] test goodwill and non-amortizable intangible assets for impairment annually.
The values of these assets may be affected by several factors, including general macroeconomic and geopolitical conditions; regulatory and legal developments; changes in product volume growth rates; changes in pricing strategies and [removed: costs] [added: cost] bases; discount rates; success of planned new product expansions; competitive activity; and income and excise taxes.
In addition to our consolidated financial results, our management regularly reviews a number of [removed: operating] [added: operating, performance, risk,] and financial metrics, including various revenue, user and sales metrics (such as market shares, in-market sales, adjusted in-market sales, and SFP users) to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions.
Furthermore, in some instances the metrics are based upon a number of assumptions and estimates [added: that, while presented with numerical specificity, are inherently subject to significant uncertainties and contingencies.]
If our management fails to account for other relevant information or [added: to] substitute the key business metrics they review as our business changes or if the assumptions or estimates underlying the metrics are inaccurate, their ability to accurately formulate financial projections and make strategic decisions may be compromised and our business, financial results and future growth prospects may be adversely impacted.
In [removed: 2024,] [added: 2025,] Russia accounted for around 9% of our total cigarette and heated tobacco unit shipment volume, and around 6% of our total net revenues.
The likelihood of [removed: retaliatory] action by the Russian government against [removed: companies, including] PMI, [removed: as a result of actions and statements made in response to the Russian invasion or otherwise,] including the possibility of legal action against us or our employees; the deprivation of rights in, or access to, our Russian or Russia-related assets; or nationalization of foreign businesses or assets (including cash reserves held in Russia and intangible assets such as trademarks), is impossible to predict.
Our strategic priority is the continued introduction, commercialization, and growth of our SFPs and if these efforts are not successful, in key markets or systematically, our financial results and future growth prospects may be materially adversely impacted.
In addition, actions of some market participants, such as the inappropriate
Governmental actions to restrict or entirely prohibit the use of certain SFP categories have also been considered or adopted in various jurisdictions.
We anticipate that significant regulatory restrictions will continue to be considered and adopted in many markets.
The success of our business in the United States is dependent on an evolving legal and regulatory framework.
Federal, state or local government action, including regulatory actions and inaction by the FDA, may have a material adverse impact on our commercialization of SFPs and in our business in the United States.
Our business is subject to changes in adult consumer preferences and if we do not accurately assess market trends, are unable to adapt our product offerings to evolving consumer demands, or face challenges in product development, we could experience missed opportunities, supply chain challenges, reduced competitiveness, inefficient expenditures, and potential impacts on our customer base and brand reputation.
Furthermore, restrictions pertaining to packaging, labeling, or promotional and advertising activities may limit our ability to effectively communicate product innovations intended to address changing adult consumer preferences.
Any of these factors could have a material adverse effect on our results of operations, revenues, cash flows, profitability, and prospects for growth.
*Risks Related to Taxation and Finance*
manufactured by certain of our competitors.
Nevertheless, some jurisdictions have considered or adopted taxation regimes with SFP taxation rates approaching or equal to cigarettes and we are unable to predict whether new regulations, or reinterpretations of existing regulations, will result in SFPs being taxed in line with other tobacco products such as conventional cigarettes in additional jurisdictions, on a prospective or retroactive basis.
Unstable geopolitical conditions or events in certain markets, including international conflicts, civil unrest, acts of war, terrorism, governmental changes, or changes in international relations could result in negative tax impacts.
Additionally, we expect that these third parties adhere to our applicable standards and to applicable laws related to product quality, responsible marketing, data protection, labor practices, and other areas.
Our ability to monitor and enforce compliance is inherently limited and these parties may fail to comply with our standards or to operate in accordance with our expectations or legal requirements, which could expose us to operational disruptions, legal or regulatory liabilities, reputational damage, or financial losses.
While we seek to mitigate the physical risks to our business associated with the natural environment through a comprehensive strategy that includes the development and implementation of robust mitigation and adaptation measures, we recognize that there are residual risks that lie beyond our operational control.
For example, increased frequency and intensity of extreme droughts, floods, and/or heatwaves could negatively affect our manufacturing operations, tobacco-growing areas, third-party operators and third-party manufacturers sites, and supply regions for products and raw materials, all of which may lead to disruption of our supply chain and of operations at factories, warehouses and other premises.
Furthermore, there is a continued and, in some cases, increased focus by certain regulatory and legislative bodies on environmental policies, including by the governmental authorities in certain international jurisdictions where we operate.These policies include, among others, carbon emissions and other environmentally focused taxation and fees as well as disclosure requirements, which could lead to additional taxation; energy price increases; disclosure and data assurance risks; new compliance costs; increased distribution and supply chain costs; and other expenses impacting our cost of operations.
Moreover, given that the regulatory landscape in this regard is highly dynamic and fragmented across the many jurisdictions where we operate, additional uncertainties may be driven by regulatory changes with limited time for implementation and by contradictory requirements across jurisdictions, which could elevate the cost or complexity of our operations or create compliance risks.
Additionally, we source the vast majority of our tobacco from a global network of farmers across multiple countries, rather than through commodity markets, which helps ensure the consistency, quality, and traceability of our tobacco supply.
However, this model also means that disruptions to farmer livelihoods, if not actively mitigated, could lead to supply chain disruption through farmer exit, reduced crop quality, unsustainable farming practices, increased regulatory scrutiny, and reputational risks.
revenue; and result in significant expense to repair or replace affected facilities.
Additionally, while we do not now expect that the recent and currently anticipated trade tariffs imposed by the U.S. and other countries will materially impact our business, the global tariff environment is volatile and further tariff or trade related developments could result in risks to PMI’s business, including increased production costs; limited market access; supplier financial condition degradation resulting in reduced or interrupted supplies; and price increases or other economic impacts that could reduce consumer demand.
Inflation can also increase financing costs due to related increases in benchmark interest rates.
Commercialization of these products is currently limited and exploratory.
Our or our business partners’ failure or inability to adhere to privacy, data, artificial intelligence and information security laws could result in reputational harm, legal liability, and adversely affect our operating results.
We increasingly use artificial intelligence-based solutions in our business, which could result in reputational harm, legal liability, and adversely affect our operating results.
We and our business partners are increasingly incorporating artificial intelligence ("AI")-based solutions in our ways of working and operations, but this process involves uncertainty and risks, which may or may not yield corresponding benefits.
Artificial intelligence technologies are complex, and there are technical and organizational challenges associated with achieving optimal levels of accuracy, efficiency, safety, explicability, reliability, and use for their intended purposes.
Flaws, biases, data sourcing issues, limitations, errors, misconfiguration, or malfunctions in these systems could result in operational disruptions, including data loss and corruption.
There is a risk of artificial intelligence system failures, disruptions, or vulnerabilities that could compromise PMI’s information technology
networks and systems and the integrity, availability, security, or privacy of PMI data processed by or through such systems.
The emergence of AI and other technologies may also exacerbate other risks, including those related to regulation, litigation, compliance issues, ethical concerns, confidentiality, intellectual property ownership and infringement, and data privacy or security.
Separately, AI presents a new attack surface that cybercriminals will attempt to exploit as well as providing means to scale and automate targeted attacks.
Ineffective or inadequate artificial intelligence development, adoption, or deployment practices, including any use, reliance, or dependence on AI generated outputs, could result in unintended, unexpected, or otherwise unforeseen adverse consequences.
These risks could have a material adverse effect on our business, reputation, financial condition, or operating results.
Our SFPs constitute a relatively new product category that is less predictable than our mature cigarette business.
Consequently, you
Our key strategic priorities are to: (i) continue developing and commercializing products that present less risk of harm to adult smokers who switch to smoke-free products versus continued cigarette smoking; and (ii) encourage and educate current adult smokers who would otherwise continue to smoke cigarettes to switch to those products.
For our efforts to be successful, we must:
| • | | | develop SFPs that adult smokers who would otherwise continue to smoke cigarettes find to be satisfying alternatives to smoking; | | |
| • | | | for those adult smokers, our goal is to develop and offer SFPs with a scientifically substantiated risk-reduction profile that approaches as closely as possible the risk-reduction profile associated with smoking cessation; | | |
| • | | | substantiate the reduction of risk for the individual adult smoker and the reduction of harm to the population as a whole, based on scientific evidence of the highest standard that is made available for scrutiny and review by external independent scientists and relevant regulatory bodies; and | | |
| • | | | advocate for the development of science-based regulatory frameworks for the development and commercialization of SFPs, including the communication of scientifically substantiated information to enable adult smokers to make better choices. | | |
We might not succeed in our effort to introduce, commercialize, and grow our SFPs in existing and new markets.
Regulatory restrictions could limit the success of our SFPs.
The World Health Organization (the "WHO") study group on tobacco product regulation published their ninth report on the scientific basis of tobacco product regulation in August 2023.
The report is based on a review of scientific evidence related to novel and emerging nicotine and tobacco products, such as electronic nicotine delivery systems ("ENDS"), electronic non-nicotine delivery systems and HTPs.
In August 2021, the Framework Convention on Tobacco Control (the "FCTC") Secretariat published two reports on novel and emerging tobacco products to the Ninth Session of the CoP of the FCTC, which are not materially different from the WHO study group report.
Substantive decisions based on these reports were deferred to the Tenth Session of the CoP ("CoP 10").
CoP 10 to the FCTC took place in February 2024.
According to reports and decisions published, neither new decisions nor new policy recommendations on novel and emerging tobacco products were adopted.
Specific Guidelines were adopted to address cross-border Tobacco Advertising, Promotion, and Sponsorship ("TAPS") and the depiction of tobacco in entertainment media.
The Eleventh Session of the CoP is currently scheduled to take place in November 2025.
If there is significant usage, whether actual or perceived, of our
Moreover, we also submitted additional premarket tobacco applications for other *ZYN* products after the September 9, 2020 deadline, and we are unable to market these products until the FDA authorizes such applications.
In April 2024, we also submitted MRTPAs for *ZYN* products currently marketed in the U.S. and requested authorization of the modified risk claim.
There is no guarantee that the *ZYN* products will receive the necessary authorizations from the FDA.
Nevertheless, we are unable to predict whether regulators will be issuing new regulations under which SFPs will be equally taxed in line with other tobacco products such as conventional cigarettes.
Significant regulatory developments will continue to take place over the next few years in most of our markets, driven principally by the Framework Convention on Tobacco Control (the "FCTC").
Since it came into force in 2005, the FCTC has led to increased efforts by tobacco control advocates and public health organizations to promote increasingly restrictive regulatory measures on the marketing and sale of tobacco and nicotine-containing products to adult nicotine users.
Such changes, as well as changes in taxing
We will continue to evaluate and monitor as additional guidance and clarification becomes available.
that, while presented with numerical specificity, are inherently subject to significant uncertainties and contingencies.
Historically, we also produced finished goods in Ukraine for export and manufactured products in Russia.
In 2022, as a result of Russia’s invasion of Ukraine, we suspended planned investments and scaled down our manufacturing operations in Russia.
For example, historically we sourced certain finished goods, production materials and components from both Russia and Ukraine, including printed materials and filters, and the invasion has, and may continue to, disrupt the availability of and impact our supply chain for these materials.
These disruptions, to the extent we are unable to find alternative sources or otherwise address these supply constraints, may impact the availability and cost of our products in other markets, which would adversely impact our business, results of operations, cash flows and financial position, and may result in impairment charges.
While we seek to mitigate our business risks associated with environmental issues, such as climate change, by establishing environmental goals and standards and seeking business partners, including within our supply chain, that are committed to operating in ways that protect the environment or mitigate environmental impacts, we recognize that there are inherent environmental-related risks, including climate change-related risks, wherever business is conducted.
Among other potential impacts, climate change could influence the quality and volume of the agricultural products we rely on, including tobacco, due to several factors beyond our control, including more frequent variations in weather patterns, extreme weather events causing unexpected downtime and inventory losses, other adverse weather conditions, and governmental restrictions on trade, all of which may lead to disruption of operations at factories, warehouses and other premises.
Furthermore, nature-related risks, including those related to natural ecosystems degradation, decreased agricultural productivity in certain regions of the world, biodiversity loss, water resource depletion and deforestation, which are partially driven or exacerbated by climate change, may negatively impact the resilience of, or otherwise disrupt, our business operations or those of our suppliers and business partners.
There is an increased focus by foreign, federal, state and local regulatory and legislative bodies on environmental policies, including those relating to climate change.
New environmental-related legal or regulatory requirements may lead to additional carbon taxation, raw or other materials taxation, energy price increases, new compliance costs, increased distribution and supply chain costs, and other expenses impacting our cost of operations.
Moreover, given that the regulatory framework in this regard is highly dynamic, additional uncertainties may be driven by further upcoming regulatory changes on which we might have limited visibility or limited time to implement, which could have an impact on several elements of our business, including elevating the cost or complexity of our operations.
Even if we make changes to align ourselves with legal or regulatory requirements, we may still be subject to significant penalties if such laws or regulations are interpreted and applied in a manner inconsistent with our practices.
For example, the global pandemic outbreak of the COVID-19 virus in 2020 created significant societal and economic disruption and the closure of stores, factories and offices, restrictions on manufacturing, distribution and travel, and supply chain disruptions, among other impacts.
An excerpt. Shown here: 40 of 81 rewritten, all 36 added and 40 of 80 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors. in the FY2025 filing and the FY2024 filing.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
415 rewritten, 224 added, 391 removed, 555 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
We are a leading international [removed: tobacco] [added: consumer goods] company, actively delivering a smoke-free future.
Our current product portfolio primarily consists of cigarettes and smoke-free [added: products, including heat-not-burn, nicotine pouch and e-vapor] products.
Since 2008, we have invested over [removed: $14] [added: $16] billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes.
[removed: Our] [added: As of December 31, 2025, our] four geographical segments [removed: are] [added: were] as follows:
- East Asia, Australia, and PMI [removed: Duty Free Region ("EA,] [added: Global Travel Retail (“EA,] AU & PMI [removed: DF");] [added: GTR”);] and
Following the sale of Vectura Group Ltd. on December 31, 2024, we [removed: will update] [added: updated] our segment reporting [added: in January 2025] by including the [removed: remaining] [added: ongoing] Wellness [removed: & Healthcare] results [added: (previously referred to as Wellness & Healthcare)] in the Europe segment.
In addition, we [removed: will be renaming] [added: renamed] our “PMI Duty Free” business to “PMI Global Travel Retail” effective in the first quarter of 2025.
As a result of this change, [removed: PMI's] [added: our] segment that includes our duty free business [removed: will be] [added: was] renamed East Asia, Australia & PMI Global Travel Retail (“EA, AU & PMI GTR”).
Our portfolio [removed: comprises] [added: is comprised of] both international and local brands.
SFB also includes wellness [removed: and healthcare] products, as well as consumer accessories, such as lighters and matches.
[removed: *IQOS* and] [added: *IQOS,*] *ZYN* [added: and *VEEV*] are the leading brands in our SFPs portfolio.
As of December 31, [removed: 2024,] [added: 2025,] our smoke-free products were available for sale in [removed: 95] [added: 106] markets.
This includes medical and [removed: pharmaceutical cannabinoids, and] non-recreational cannabinoid products (including CBD), in line with applicable regulatory requirements, though any revenue related to cannabinoids is expected to be negligible in the near to medium term.
[removed: In 2022,] [added: As of April 30, 2024,] we [removed: reached] [added: hold the full rights to commercialize *IQOS* in the U.S. after reaching] an agreement [removed: with Altria Group, Inc.] to end our [added: U.S.] commercial relationship [removed: in the U.S.] covering *IQOS* [removed: as of April 30, 2024.][added: with Altria Group, Inc. in 2022.]
Our net revenues and operating income are affected by various factors, including the volume [added: and mix] of products we sell, the price of our [removed: products,] [added: products and] changes in currency exchange [removed: rates and the mix of products we sell.][added: rates.]
[removed: Mix] [added: "Mix"] can also refer to the proportion of shipment volume in more profitable markets versus shipment volume in less profitable markets (geographic mix).
Our cost of sales consists [removed: principally] [added: primarily] of: tobacco leaf, non-tobacco raw materials, labor and manufacturing costs; shipping and handling costs; and the cost of devices produced by third-party electronics manufacturing service providers.
[added: *Impairment related to the RBH equity investment* –] On October 17, 2024, the court-appointed mediator and monitor in the [removed: CCAA] [added: Companies' Creditors Arrangement Act ("CCAA")] proceedings filed a proposed plan of compromise and arrangement (“Proposed Plan”) setting forth, among other things, certain terms of a proposed comprehensive resolution of Canadian tobacco claims and related litigation.
Under the resolution contemplated by the Proposed Plan, RBH, Imperial Tobacco Canada Limited ("ITL") and JTI Macdonald Corp ("JTIM") would pay an aggregate global settlement amount of CAD 32.5 billion (approximately [removed: $22.3 billion).][added: $23.7 billion as of December 31, 2025).]
On January 24, 2025, RBH filed an objection to approval of the Proposed Plan with the CCAA [removed: court (for further details, see Item 8, Note 18.][added: court.]
Although there [removed: remains] [added: remained] some uncertainty as to the final terms of the Proposed plan, PMI evaluated its investment in RBH for potential impairment and concluded that the estimated fair value of its investment in RBH was lower than its carrying value.
For further details, see Item 8, Note [removed: 6.][added: 4.]
- Net Revenues – Net revenues of [removed: $37.9] [added: $40.6] billion for the year ended December 31, [removed: 2024,] [added: 2025,] increased by [removed: $2.7] [added: $2.8] billion, or [removed: 7.7%,] [added: 7.3%,] from the comparable [removed: 2023] [added: 2024] amount.
The change in our net revenues from the comparable [removed: 2023] [added: 2024] amount was driven by the following (variances not to scale):
[removed: ][added: ]
Net revenues increased by [removed: 7.7%.][added: 7.3%.]
Net revenues by product category for the years ended December 31, [removed: 2024] [added: 2025] and [removed: 2023,] [added: 2024,] are shown below:
[removed:  ][added:  ]
- Diluted Earnings Per Share – The changes in our reported diluted earnings per share (“diluted EPS”) for the year ended December 31, [removed: 2024,] [added: 2025,] from the comparable [removed: 2023] [added: 2024] amounts, were as follows:
| [removed: For] [added: For] the [removed: year ended] [added: Year Ended] December 31, [removed: 2023] [added: 2023] | | | [removed: $] | [removed: 5.02] | | | | | [added: | | | | | | | | |]
| [removed: 2023] [added: 2024] Fair value adjustment for equity security investments | | | [removed: (0.02)] [added: (0.27)] | | | | | |
| [removed: 2023] [added: 2024] Income tax impact associated with Swedish Match AB financing | | | [removed: (0.11)] [added: 0.14] | | | | | |
| [removed: 2023] [added: 2025] Tax items | | | 0.11 | | | | | |
| 2024 Restructuring charges | | | [removed: (0.10)] [added: 0.10] | | | | | |
| 2024 Impairment of other intangibles | | | [removed: (0.01)] [added: 0.01] | | | | | |
| [removed: 2024] [added: 2025] Fair value adjustment for equity security investments | | | [removed: 0.27] [added: 0.18] | | | | | |
| 2024 Impairment related to RBH equity investment | | | [removed: (1.49)] [added: 1.49] | | | | | |
| 2024 Amortization of intangibles | | | [removed: (0.40)] [added: 0.40] | | | | | |
| 2024 Loss on sale of Vectura Group | | | [removed: (0.13)] [added: 0.13] | | | | | |
| 2024 Egypt sales tax charge | | | [removed: (0.03)] [added: 0.03] | | | | | |
- Europe Region, including our Wellness business;
As communicated in the fourth quarter of 2025, with our smoke-free business now operating at scale across our regions, including substantial growth from our U.S. business, we have implemented an evolved organizational model with two primary business units: International and U.S. The updated organizational structure is designed to enhance our agility and to support our journey to become a smoke-free company under the leadership of Jacek Olczak, Group CEO of PMI.
This change was implemented effective January 1, 2026, and as a result we realigned our reportable segments accordingly.
The four geographic segments have been replaced with three new reportable segments: International Smoke-Free, International Combustibles, and U.S. As of the first quarter of 2026, our reporting will reflect these changes.
With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas.
The business strategy of our wellness unit, Aspeya, currently focuses on developing and commercializing primarily oral consumer wellness offerings.
| 2025 Restructuring charges | | | (0.14) | | | | | |
| 2025 Impairment of goodwill | | | (0.03) | | | | | |
| 2025 Amortization of intangibles | | | (0.50) | | | | | |
| 2025 Germany excise tax classification litigation charge | | | (0.10) | | | | | |
| 2025 RBH (Canada) Plan implementation, including dividend income, net | | | 0.10 | | | | | |
| 2025 Impairment of Wellness business related equity investment | | | (0.09) | | | | | |
| 2025 Loss on expected sale of consumer accessories and other businesses | | | (0.06) | | | | | |
| Subtotal of 2025 items | | | (0.28) | | | | | |
| Currency | | | 0.04 | | | | | |
| Interest | | | 0.09 | | | | | |
| Operations | | | 0.85 | | | | | |
Consequently, PMI recorded a goodwill impairment charge of $41 million (representing a $0.03 per share decrease in diluted EPS).
*Megapolis localization tax impact* – PMI holds a 23% equity interest in JSC TK Megapolis ("TKM"), PMI's distributor in Russia (SSEA, CIS & MEA segment).
*Germany excise tax classification litigation charge* *–* In August 2024, the German Main Custom Office (“MCO”) notified Philip Morris (Germany) GmbH (“PM Germany”) of its decision to classify *TEREA* consumables as a cigarette for excise tax purposes with the associated tax assessment totaling EUR 151 million (approximately $176 million) covering the period of February 15, 2023, through August 1, 2024.
In April 2025, PM Germany paid the outstanding amount, which was recorded in Other assets on the consolidated balance sheets, while it challenged the MCO’s decision in court.
On September 17, 2025, PM Germany filed a request to withdraw the proceedings.
*RBH (Canada) Plan implementation, including dividend income, net* *–* On August 29, 2025, the plan of compromise and arrangement (the “Plan”) setting forth the terms of a resolution of Canadian tobacco claims and related litigation became effective.
In the third quarter of 2025, we recorded after-tax income of $156 million ($0.10 per share increase in diluted EPS) following the Plan implementation, including $303 million of dividend income net of the corresponding decrease in the carrying value of the RBH investment, $19 million of other income and the related income tax charge of $166 million.
*Impairment of Wellness business related equity investment* *–* In the third quarter of 2025, PMI recorded a non-cash after-tax charge of $146 million (representing a diluted EPS charge of $0.09 per share), primarily representing an other-than-temporary impairment of one equity method investment within the Wellness business following a reassessment of its estimated fair value triggered by the amendment of existing investment agreements in the third quarter of 2025.
The impairment charge was recorded in equity investments and securities (income)/loss, net in the consolidated statements of earnings for the year ended December 31, 2025.
*Loss on expected sale of consumer accessories and other businesses* *–* During the fourth quarter of 2025, PMI completed the sale of one business and classified as held-for-sale net assets of certain other businesses (disposal group), primarily related to its consumer accessories products acquired as part of the Swedish Match AB acquisition in 2022.
As a result, PMI recorded a pre-tax loss of $94 million (representing a diluted EPS charge of $0.06 per share).
The 2025 tax items that increased our 2025 diluted EPS by $0.11 per share in the table above were due to benefits related to an interest expense election primarily driven by a reduction in prior year tax costs associated with global intangible low-taxed income and refunds expected on amended tax returns filed in Germany; partially offset by valuation allowances recorded on deferred tax assets related to U.S. foreign tax credits and the recognition of current tax expense related to the potential disallowance of deductions for certain intercompany transactions in Indonesia.
*Income Taxes.*
*Interest* – The favorable impact of $0.09 per share from interest in the table above was primarily due to the impact of lower market interest rates on our variable-rate debt, as well as the favorable impact of derivative financial instruments.
- EA, AU & PMI GTR: Favorable volume/mix and a favorable pricing variance;
partly offset by
Our
As discussed in Item 8, Note 4.*Goodwill and Other Intangible Assets, net*, PMI recorded impairment losses related to goodwill and non-amortizable intangible assets during the second quarter of 2025 and 2023, where certain reporting units and non-amortizable intangible assets were written down to their respective fair values as of the date of the annual impairment review.
At December 31, 2025, the carrying value of our goodwill was $17.3 billion.
All assumptions used in the impairment assessments for goodwill and non-amortizable intangible assets are based on the best available market information and are consistent with PMI’s internal forecasts and operating plans.
A deterioration in these assumptions could adversely impact our results.
| | | | 2025 | | | 2024 | | |
PMI records derivative contracts at their fair value in accordance with U.S. GAAP and assesses their fair value using standard valuation models that rely on readily observable market inputs.
Following the combination and the progress in 2023 toward the integration of the Swedish Match business into PMI's existing regional structure, PMI updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments.
- Europe Region;
Our Wellness and Healthcare segment ("W&H") remained unchanged in 2024.
As of the first quarter of 2025, our reporting will reflect these changes.
Our Wellness and Healthcare business strategy focuses on developing and commercializing oral and inhaled consumer health and wellness offerings and inhaled prescription products for therapy areas that include pain management and cardiovascular emergencies.
In 2022, we acquired Swedish Match AB, a market leader in oral nicotine delivery with a significant presence in the United States market.
The Swedish Match acquisition was a key milestone in PMI’s transformation to becoming a smoke-free company.
The Swedish Match product portfolio is complementary to our portfolio, permitting us to bring together a leading oral nicotine product with the leading heat-not-burn product.
PMI now holds the full rights to commercialize *IQOS* in the U.S.
For further details of our 2022 acquisition of Swedish Match, as well as the agreement with Altria Group, Inc. discussed above, see Item 8, Note 3.
*Acquisitions and Divestitures* and the "Business Environment" section of this Item 7.
Philip Morris International Inc. is a legal entity separate and distinct from its direct and indirect subsidiaries.
Accordingly, our right, and thus the right of our creditors and stockholders, to participate in any distribution of the assets or earnings of any subsidiary is subject to the prior rights of creditors of such subsidiary, except to the extent that claims of our company itself as a creditor may be recognized.
As a holding company, our principal sources of funds, including funds to make payment on our debt securities, are from the receipt of dividends and repayment of debt from our subsidiaries.
*Impairment Related to the Rothmans, Benson & Hedges Equity Investment*
A significant determinative factor in the analysis of impairment indicators was the issue of allocation of CAD 32.5 billion aggregate settlement amount among RBH, ITL, and JTIM which remained unresolved at the time of filing.
*Contingencies*).
Developments, including the positions taken by RBH in this objection and the positions taken by other parties in related filings narrowed the range of possible outcomes with respect to the allocation of the aggregate settlement amount of CAD 32.5 billion among RBH, ITL, and JTIM, which was determined to be an indicator that PMI’s investment in RBH may be impaired.
As a result, PMI performed a quantitative valuation of its investment in RBH as of December 31, 2024, and recorded a non-cash impairment charge of $2,316 million (representing a diluted EPS charge of $1.49 per share) in the consolidated statement of earnings for the year ended December 31, 2024, as a recognized subsequent event.
Net revenues, excluding currency and acquisitions, increased by 10.1%, mainly reflecting: a favorable pricing variance, primarily driven by higher combustible tobacco pricing; and favorable volume/mix, driven by higher smoke-free products volume, partly offset by unfavorable cigarette mix, as well as a favorable comparison to 2023 reflecting a charge in the first quarter of 2023 of $80 million following the termination of a distribution arrangement in the Middle East, shown in "Other." The termination of a distribution arrangement in the Middle East is further described in the following "*Diluted Earnings Per Share*" discussion.
| 2023 Charges related to the war in Ukraine | | | 0.03 | | | | | |
| 2023 Restructuring charges | | | 0.06 | | | | | |
| 2023 South Korea indirect tax charge | | | 0.11 | | | | | |
| 2023 Termination of agreement with Foundation for a Smoke-Free World | | | 0.07 | | | | | |
| 2023 Amortization of intangibles | | | 0.25 | | | | | |
| 2023 Impairment of goodwill and other intangibles | | | 0.44 | | | | | |
| 2023 Termination of distribution arrangement in the Middle East | | | 0.04 | | | | | |
| 2023 Swedish Match AB acquisition accounting related items | | | 0.01 | | | | | |
| Subtotal of 2023 items | | | 0.99 | | | | | |
| Currency | | | (0.38) | | | | | |
| Interest | | | (0.03) | | | | | |
| Operations | | | 1.04 | | | | | |
*Charges related to the war in Ukraine –* During 2023, we recorded a pre-tax charge of $53 million (representing $43 million net of income tax and a diluted EPS charge of $0.03 per share), related to circumstances driven by the war, including the cost of PMI’s humanitarian efforts, severance payments, as well as an impairment of certain long-lived assets.
*War in Ukraine*.
*South Korea indirect tax charge* *–* On July 13, 2023, our South Korean subsidiary, PM Korea, received an adverse ruling from the Supreme Court of South Korea related to cases alleging underpayment of excise taxes in connection with a 2015 excise tax increase and subsequent audit by the South Korean Board of Audit and Inspection.
The Supreme Court ruling reversed previous decisions that were in PM Korea’s favor at the trial and appellate levels.
As a result of the ruling, we concluded that an adverse outcome was probable.
Consequently, we recorded a non-cash pre-tax charge of $204 million (representing $174 million net of income tax or $0.11 per share decrease in diluted EPS) in the second quarter results of 2023, reflecting the full amount previously paid by PM Korea.
*Termination of agreement with Foundation for a Smoke-Free World* – On September 29, 2023, PMI and the Foundation for a Smoke-Free World (the "Foundation") entered into the Final Grant Agreement and Termination of the Second Amended and Restated Pledge Agreement ("Agreement").
Under the terms of the Agreement, PMI paid $140 million in the third quarter of 2023 in return for the termination of the pledge agreement between the parties.
An excerpt. Shown here: 40 of 415 rewritten, 40 of 224 added and 40 of 391 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. in the FY2025 filing and the FY2024 filing.
Item 1. Business.
51 rewritten, 17 added, 25 removed, 124 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
We are a leading international [removed: tobacco] [added: consumer goods] company, actively delivering a smoke-free future and evolving our portfolio for the long term to include products outside of the tobacco and nicotine sector.
Our current product portfolio primarily consists of cigarettes and smoke-free [added: products, including heat-not-burn, nicotine pouch and e-vapor] products.
Since 2008, we have invested over [removed: $14] [added: $16] billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes.
[removed: In 2022,] [added: As of April 30, 2024,] we [removed: reached] [added: hold the full rights to commercialize *IQOS* in the U.S. after reaching] an agreement [removed: with Altria Group, Inc.] to end our [added: U.S.] commercial relationship [removed: in the U.S.] covering *IQOS* [removed: as of April 30, 2024.][added: with Altria Group, Inc. in 2022.]
This includes medical and [removed: pharmaceutical cannabinoids, and] non-recreational cannabinoid products (including CBD), in line with applicable regulatory requirements, though any revenue related to cannabinoids is expected to be negligible in the near to medium term.
SFB also includes wellness [removed: and healthcare] products, as well as consumer accessories, such as lighters and matches.
We put significant effort to restrict access of our products from [removed: non-smokers and youth.][added: underage persons.]
Heated tobacco units ("HTUs") is the term we use to refer to heated tobacco consumables, which include our *BLENDS*, *DELIA*, *HEETS*, *HEETS Creations* (defined collectively as "*HEETS*"), *SENTIA*, *TEREA,* *TEREA CRAFTED and TEREA Dimensions,* as well [added: as the KT&G-licensed brands, *Fiit* and *Miix* (outside of South Korea).]
[removed: *IQOS* and] [added: *IQOS,*] *ZYN* [added: and *VEEV*] are the leading brands in our SFPs portfolio.
As of December 31, [removed: 2024,] [added: 2025,] our smoke-free products were available for sale in [removed: 95] [added: 106] markets.
With regard to [removed: nicotine] [added: modern oral] pouches, we increased our presence to [removed: 37] [added: 56] markets.
Our portfolio comprises both international and local brands and is led by *Marlboro*, the world’s best-selling international cigarette, which accounted for approximately [removed: 40%] [added: 43%] of our total [removed: 2024] [added: 2025] cigarette shipment volume.
[removed: Our other leading] international cigarette brands are *Chesterfield, L&M*, and *Philip Morris.* These five international cigarette brands contributed [removed: 80%] [added: 81%] of our cigarette shipment volume in [removed: 2024.][added: 2025.]
[removed: Our] [added: As of December 31, 2025, our] four geographical segments [removed: are] [added: were] as follows:
- Europe Region is headquartered in Lausanne, Switzerland, and covers all the European Union countries, Switzerland, the United Kingdom, and also Ukraine, Moldova and Southeast Europe; [added: it also includes our Wellness business;]
- East Asia, Australia, and PMI [removed: Duty Free Region] [added: Global Travel Retail] ("EA, AU & PMI [removed: DF")] [added: GTR")] is headquartered in Hong Kong, and includes the consolidation of our [removed: international duty free] [added: global travel retail] business with East Asia & Australia; and
Following the sale of Vectura Group Ltd. on December 31, 2024, we [removed: will update] [added: updated] our segment reporting [added: in January 2025] by including the [removed: remaining] [added: ongoing] Wellness [removed: & Healthcare] results [added: (previously referred to as Wellness & Healthcare)] in the Europe segment.
In addition, we [removed: will be renaming] [added: renamed] our “PMI Duty Free” business to “PMI Global Travel Retail” effective in the first quarter of 2025.
As a result of this change, [removed: PMI's] [added: our] segment that includes our duty free business [removed: will be] [added: was] renamed East Asia, Australia & PMI Global Travel Retail (“EA, AU & PMI GTR”).
References in this Form 10-K to total international market, defined as worldwide cigarette and heated tobacco unit volume, excluding the United States, total industry (or total market) and market shares, are our estimates for tax-paid [added: and Global Travel Retail] products based on data from a number of internal and external sources, and may, in defined instances, exclude China.
Unless otherwise stated, references to total industry [removed: (or total market), our shipment volume] and our market share performance reflect cigarettes and heated tobacco units.
| | | | [removed: 2024] [added: 2025] | | | [removed: 2023] [added: 2024] | | | [removed: 2022] [added: 2023] | | |
| Total Market, billion units (excluding China and the U.S.) | | | [removed: 2,618] [added: 2,587] | | | [removed: 2,579] [added: 2,596] | | | [removed: 2,621] [added: 2,560] | | |
| Total International Market Share (1) | | | [removed: 28.7%] [added: 29.2%] | | | [removed: 28.3%] [added: 29.0%] | | | [removed: 27.7%] [added: 28.6%] | | |
| PMI Cigarette over Cigarette Market Share (2) | | | 25.3% | | | [removed: 25.2%] [added: 25.5%] | | | [removed: 25.0%] [added: 25.4%] | | |
| *Marlboro* Cigarette over Cigarette Market Share (3) | | | [removed: 10.1%] [added: 10.7%] | | | [removed: 9.8%] [added: 10.2%] | | | 9.8% | | |
We have a market share of at least 15% in approximately 100 markets, including Algeria, Argentina, Australia, Austria, [removed: Belgium,] Brazil, the Czech Republic, Egypt, France, Germany, Greece, Hong Kong, Hungary, Indonesia, [removed: Israel,] Italy, Japan, Kazakhstan, [removed: Kuwait,] Mexico, the Netherlands, the Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, the Slovak Republic, South Korea, Spain, [removed: Switzerland, Turkey] [added: Switzerland] and [removed: Ukraine.][added: Turkey.]
The competitive environment and our competitive position can be significantly influenced by weak economic conditions; erosion of consumer confidence; competitors' introduction of lower-price products or innovative products; adult smoker willingness to convert to our SFPs; higher product taxes; higher absolute prices and larger gaps between retail price categories; and product regulation that diminishes the ability to differentiate [removed: tobacco] products, restricts adult consumer access to truthful and non-misleading information about our SFPs, or disproportionately impacts the commercialization of our products in relation to our competitors.
Some [added: of our] competitors have different profit, volume and regulatory objectives, and some international competitors may be less susceptible than PMI to changes in currency exchange rates.
Certain [removed: new market entrants in the non-combustible product category] [added: SFP competitors] may alienate consumers from innovative products through inappropriate marketing campaigns, messaging and inferior product satisfaction, and without scientific substantiation based on appropriate R&D protocols and standards.
In [removed: 2024,] [added: 2025,] we also contracted directly with farmers in several countries, including Argentina, Brazil, Italy, Pakistan and Poland.
In [removed: 2024,] [added: 2025,] direct sourcing from farmers represented approximately [removed: 18%] [added: 23%] of PMI’s global leaf requirements.
In [removed: addition to tobacco leaf,] [added: 2025,] we [removed: purchase] [added: purchased] a wide variety of direct materials from a total of approximately [removed: 500] [added: 350] suppliers.
In [removed: 2024,] [added: 2025,] our top ten suppliers of direct materials combined represented approximately 60% of our total direct materials purchases.
[removed: Our devices] [added: Additionally, we purchase electronic devices, which] are made by various electronic manufacturing services providers ("EMS").
In [removed: 2024,] [added: 2025,] sales to a distributor in the Europe Region and a distributor in the EA, AU & PMI [removed: DF] [added: GTR] Region each amounted to 10 percent or more of our consolidated net revenues.
See Item 8, Note [removed: 13.][added: 11.]
In some of our markets, particularly in the Europe, SSEA, CIS & MEA, and EA, AU & PMI [removed: DF] [added: GTR] Regions, a loss of a distributor may result in a temporary market disruption.
Our Workforce*.* At December 31, [removed: 2024,] [added: 2025,] we employed approximately [removed: 83,100] [added: 84,900] people worldwide, including full-time, temporary and part-time staff.
We are proud of the global reach of our company, [removed: which operates in] [added: with] approximately 170 markets [added: where we have sold our products, and] with employees representing more than 130 [removed: nationalities.][added: nationalities as of December 31, 2025.]
With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness areas.
The business strategy of our wellness unit, Aspeya, currently focuses on developing and commercializing primarily oral consumer wellness offerings.
Our other leading
As communicated in the fourth quarter of 2025, with our smoke-free business now operating at scale across our regions, including substantial growth from our U.S. business, we have implemented an evolved organizational model with two primary business units: International and U.S. The updated organizational structure is designed to enhance our agility and to support our journey to become a smoke-free company under the leadership of Jacek Olczak, Group CEO of PMI.
This change was implemented effective January 1, 2026, and as a result we realigned our reportable segments accordingly.
The four geographic segments have been replaced with three new reportable segments: International Smoke-Free, International Combustibles, and U.S. As of the first quarter of 2026, our reporting will reflect these changes.
Our shipment volume in 2025, including cigarettes and smoke-free products (in equivalent units) were as follows:
| Full-Year 2025 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | Total PMI | | | | | | SFP | | | | | | *HTU* | | | | | | *Oral SFP* | | | | | | *E-vapor* | | | | | | Cigarettes | | |
| Total Shipment Volume (equivalent units in billions) | | | | | | 786.5 | | | | | | 179.1 | | | | | | 155.1 | | | | | | 20.7 | | | | | | 3.3 | | | | | | 607.4 | | |
| vs. 2024 | | | | | | 1.4% | | | | | | 12.8% | | | | | | *11.0%* | | | | | | *18.5%* | | | | | | *+100%* | | | | | | (1.5)% | | |
Oral smoke-free products conversion: (i) nicotine pouches (units): 15 pouches per can in the U.S. and approximately 20 pouches per can outside the U.S.; (ii) snus products: weighted average 21 pouches equivalent per can; (iii) moist snuff products: weighted average 17 pouches equivalent per can; (iv) tobacco bits products: weighted average 30 pouches equivalent per can; (v) chew bags products: weighted average 20 pouches per can.
E-vapor products conversion: one milliliter of e-vapor liquid equivalent to 10 units.
| Cigarettes | | | 23.4% | | | 23.7% | | | 23.8% | | |
| HTU | | | 5.8% | | | 5.3% | | | 4.7% | | |
Some market participants who sell products that directly compete with ours are circumventing applicable regulations or adopting regulatory interpretations that, in the absence of regulatory intervention and/or enforcement, could lead to an unfair competitive environment in certain markets where we operate.
of our management programs.
Through our acquisition of Swedish Match in 2022, with its leading nicotine pouch franchise in the U.S. under the *ZYN* brand name, we acquired a market leader in oral nicotine delivery with a significant presence in the United States market.
The Swedish Match acquisition has been a key milestone in PMI’s transformation to becoming a smoke-free company.
The Swedish Match product portfolio is complementary to our existing portfolio, permitting us to bring together a leading oral nicotine product with the leading heat-not-burn product.
By joining forces with Swedish Match, we expect to accelerate the achievement of our joint smoke-free ambitions, switching more adults who would otherwise continue to smoke cigarettes to better alternatives faster than either company could achieve separately.
PMI now holds the full rights to commercialize *IQOS* in the U.S. For further details, see Item 8, Note 3.
*Acquisitions and Divestitures*.
In 2021, we began our long-term growth ambitions beyond nicotine in wellness and healthcare given our strong foundation and significant expertise in life sciences.
Our Wellness and Healthcare business strategy currently focuses on developing and commercializing oral and inhaled consumer health and wellness offerings and inhaled prescription products for therapy areas that include pain management and cardiovascular emergencies.
as the KT&G-licensed brands, *Fiit* and *Miix* (outside of South Korea).
Following the combination and the progress in 2023 toward the integration of the Swedish Match business into PMI's existing regional structure, PMI updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments.
Our Wellness and Healthcare ("W&H") segment, which includes the operating results of our Wellness and Healthcare business, remained unchanged in 2024.
As of the first quarter of 2025, our reporting will reflect these changes.
Our total shipment volume, including cigarettes and heated tobacco units, increased by 2.5% in 2024 to 756.6 billion units, with shipment volume of heated tobacco units reaching 139.7 billion units in 2024, up from 125.3 billion units in 2023.
Shipment volume of our principal cigarette brand, *Marlboro*, increased by 3.7% in 2024.
| Cigarettes | | | 23.5% | | | 23.7% | | | 23.6% | | |
| HTU | | | 5.2% | | | 4.7% | | | 4.1% | | |
These business practices are intended to mitigate the risk that climate change could influence weather patterns in ways that negatively impact the quality or cost of the agricultural products used to manufacture our products.
We report externally about our climate change mitigation strategy, together with associated targets and results in reducing our carbon footprint, through CDP (formerly known as the Carbon Disclosure Project), the leading international non-governmental organization assessing the work of thousands of companies worldwide in the area of environmental impact, including climate change.
Furthermore, we have engaged an external certification body to validate the effectiveness of this management program at our manufacturing centers around the world, in accordance with internationally recognized standards ISO 14001 and ISO 45001 for safety and environmental management.
Furthermore, we progressively certify our manufacturing centers against AWS (Alliance for Water Stewardship) and Carbon Neutrality, requiring improvement actions year on year.
More specifically, any regulatory requirements that lead to a commoditization of tobacco products or impede adult consumers' ability to convert to our SFPs, as well as any significant increase in the cost of complying with new regulatory requirements could have a material adverse effect on our financial results.
Further, tightened climate-related regulation may lead to additional carbon taxation or energy price increases impacting our cost of operation.
These shifts in regulation and other market trends could, amongst others, impact current deforestation rates.
Availability of deforestation-free materials could be impacted by increased demand for alternative energy sources and low-carbon fuels, such as biomass, which could result in increased sourcing costs.
without admission of liability; (ii) the Limited Exclusion Order and Cease and Desist Order issued by the International Trade Commission on September 29, 2021, prohibiting the importation of certain heat-not-burn products by PMI and its affiliates into the United States was rescinded; and (iii) any injunctions granted to either party in the Proceedings were fully and finally discharged, without admission of liability.
An excerpt. Shown here: 40 of 51 rewritten, all 17 added and all 25 removed. The counts are complete. For every sentence, read Item 1. Business. in the FY2025 filing and the FY2024 filing.
Item 3. Legal Proceedings.
1 rewritten, 0 added, 0 removed, 1 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
The information called for by this Item is incorporated herein by reference to Item 8, Note [removed: 18.][added: 16.]
Cover and table of contents
29 rewritten, 1 added, 1 removed, 74 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
For the fiscal year ended December 31, [removed: 2024][added: 2025]
| 2.750% Notes due [removed: 2025] [added: 2029] | | | | | | [removed: PM25] [added: PM29D] | | | | | | New York Stock Exchange | | |
| [removed: 3.375%] [added: 3.250%] Notes due [removed: 2025] [added: 2032] | | | | | | [removed: PM25A] [added: PM32] | | | | | | New York Stock Exchange | | |
As of June 30, [removed: 2024,] [added: 2025,] the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately [removed: $158] [added: $283] billion based on the closing sale price of the common stock as reported on the New York Stock Exchange.
| Class | | | | | | Outstanding at | | | January [removed: 31, 2025] [added: 30, 2026] | | |
| Common Stock, no par value | | | | | | [removed: 1,554,857,221] [added: 1,556,679,579] | | | shares | | |
| Portions of the registrant’s definitive proxy statement for use in connection with its annual meeting of shareholders to be held on May [removed: 7, 2025,] [added: 6, 2026,] to be filed with the Securities and Exchange Commission on or about March [removed: 27, 2025.] [added: 26, 2026.] | | | Part III | | |
| Item 1. | | | | | | Business | | | [removed: [1](#id5122b52f33945ab8feddeff77f46ff7_13)] [added: [1](#i94fca11542804e3f9f5e986269197803_13)] | | |
| Item 1A. | | | | | | Risk Factors | | | [removed: [7](#id5122b52f33945ab8feddeff77f46ff7_16)] [added: [7](#i94fca11542804e3f9f5e986269197803_16)] | | |
| Item 1B. | | | | | | Unresolved Staff Comments | | | [removed: [19](#id5122b52f33945ab8feddeff77f46ff7_19)] [added: [18](#i94fca11542804e3f9f5e986269197803_19)] | | |
| Item 1C. | | | | | | Cybersecurity | | | [removed: [19](#id5122b52f33945ab8feddeff77f46ff7_22)] [added: [18](#i94fca11542804e3f9f5e986269197803_22)] | | |
| Item 2. | | | | | | Properties | | | [removed: [21](#id5122b52f33945ab8feddeff77f46ff7_25)] [added: [20](#i94fca11542804e3f9f5e986269197803_25)] | | |
| Item 3. | | | | | | Legal Proceedings | | | [removed: [21](#id5122b52f33945ab8feddeff77f46ff7_28)] [added: [20](#i94fca11542804e3f9f5e986269197803_28)] | | |
| Item 4. | | | | | | Mine Safety Disclosures | | | [removed: [21](#id5122b52f33945ab8feddeff77f46ff7_31)] [added: [21](#i94fca11542804e3f9f5e986269197803_31)] | | |
| Item 5. | | | | | | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | | | [removed: [22](#id5122b52f33945ab8feddeff77f46ff7_37)] [added: [21](#i94fca11542804e3f9f5e986269197803_37)] | | |
| Item 6. | | | | | | [removed: [\[Reserved\]](#id5122b52f33945ab8feddeff77f46ff7_40)] [added: [\[Reserved\]](#i94fca11542804e3f9f5e986269197803_40)] | | | [removed: [25](#id5122b52f33945ab8feddeff77f46ff7_40)] [added: [24](#i94fca11542804e3f9f5e986269197803_40)] | | |
| Item 7. | | | | | | Management’s Discussion and Analysis of Financial Condition and Results of Operations | | | [removed: [25](#id5122b52f33945ab8feddeff77f46ff7_43)] [added: [24](#i94fca11542804e3f9f5e986269197803_43)] | | |
| Item 7A. | | | | | | Quantitative and Qualitative Disclosures About Market Risk | | | [removed: [75](#id5122b52f33945ab8feddeff77f46ff7_100)] [added: [65](#i94fca11542804e3f9f5e986269197803_106)] | | |
| Item 8. | | | | | | Financial Statements and Supplementary Data | | | [removed: [76](#id5122b52f33945ab8feddeff77f46ff7_103)] [added: [66](#i94fca11542804e3f9f5e986269197803_109)] | | |
| Item 9. | | | | | | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | | | [removed: [147](#id5122b52f33945ab8feddeff77f46ff7_208)] [added: [130](#i94fca11542804e3f9f5e986269197803_214)] | | |
| Item 9A. | | | | | | Controls and Procedures | | | [removed: [147](#id5122b52f33945ab8feddeff77f46ff7_211)] [added: [130](#i94fca11542804e3f9f5e986269197803_217)] | | |
| Item 9B. | | | | | | Other Information | | | [removed: [147](#id5122b52f33945ab8feddeff77f46ff7_214)] [added: [130](#i94fca11542804e3f9f5e986269197803_220)] | | |
| Item 9C. | | | | | | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | | | [removed: [147](#id5122b52f33945ab8feddeff77f46ff7_217)] [added: [130](#i94fca11542804e3f9f5e986269197803_223)] | | |
| Item 10. | | | | | | Directors, Executive Officers and Corporate Governance | | | [removed: [147](#id5122b52f33945ab8feddeff77f46ff7_223)] [added: [130](#i94fca11542804e3f9f5e986269197803_229)] | | |
| Item 11. | | | | | | Executive Compensation | | | [removed: [150](#id5122b52f33945ab8feddeff77f46ff7_226)] [added: [132](#i94fca11542804e3f9f5e986269197803_232)] | | |
| Item 12. | | | | | | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | | | [removed: [150](#id5122b52f33945ab8feddeff77f46ff7_229)] [added: [132](#i94fca11542804e3f9f5e986269197803_235)] | | |
| Item 13. | | | | | | Certain Relationships and Related Transactions, and Director Independence | | | [removed: [150](#id5122b52f33945ab8feddeff77f46ff7_232)] [added: [133](#i94fca11542804e3f9f5e986269197803_238)] | | |
| Item 14. | | | | | | Principal [removed: Accounting] [added: Accountant] Fees and Services | | | [removed: [150](#id5122b52f33945ab8feddeff77f46ff7_235)] [added: [133](#i94fca11542804e3f9f5e986269197803_241)] | | |
| Item 15. | | | | | | Exhibits and Financial Statement Schedules | | | [removed: [151](#id5122b52f33945ab8feddeff77f46ff7_241)] [added: [134](#i94fca11542804e3f9f5e986269197803_247)] | | |
| Signatures | | | | | | | | | [142](#i94fca11542804e3f9f5e986269197803_250) | | |
| Signatures | | | | | | | | | [158](#id5122b52f33945ab8feddeff77f46ff7_244) | | |
Item 1C. Cybersecurity.
11 rewritten, 0 added, 1 removed, 31 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
Our cybersecurity risk program, managed by our Chief Information Security Officer [removed: (“CISO”)] and the information security team, is conducted under our enterprise risk management framework and operates on a risk-based approach in assessing risks from cybersecurity threats, as follows:
Our [removed: CISO] [added: Chief Information Security Officer] presents reports to the Audit and Risk Committee or to the full Board of Directors at least quarterly, which reports include cybersecurity risk status along with key performance indicators and key risk response strategies and plans.
The Corporate Risk Governance Committee includes our [added: Group CEO PMI;] Chief [removed: Executive Officer (“CEO”),] [added: Risk Assurance Officer;] Chief [added: Global R&D Officer; Chief Information Security Officer; Global Head Enterprise Risk Management; Group Chief] Financial [removed: Officer (“CFO”),] [added: Officer; Group Controller; Vice President, Associate] General Counsel [removed: (“GC”), Senior] [added: & Corporate Secretary;] Vice [removed: President Operations,] [added: President, Associate General Counsel & Group Chief Compliance Officer, Group Chief Legal Officer; Chief Global Operations Officer; Chief Global Communications Officer;] and our Chief [added: Global] Digital & Information [removed: Officer (“CDIO”).][added: Officer.]
Cybersecurity incidents that have been determined to meet established SEC reporting consideration thresholds are promptly communicated to the Disclosure Committee, which is responsible for evaluating the potential materiality of such incidents and ensuring the accuracy, timeliness and completeness of related disclosures under applicable reporting obligations, and other relevant [added: communications or presentations.]
The Disclosure Committee’s membership includes the following executives: the [added: Vice President, Associate General Counsel &] Corporate Secretary; the [removed: GC; the CFO;] [added: Group Chief Legal Officer;] the [removed: Controller & Principal Accounting] [added: Group Chief Financial] Officer; the [added: Group Controller; the] Chief Risk Assurance Officer; and the Vice President, Investor [removed: Relations.][added: Relations & Financial Communication.]
In addition, the [removed: CISO] [added: Chief Information Security Officer] serves as an advisor to the Disclosure Committee.
The [removed: CISO] [added: Chief Information Security Officer] has served in various roles in information technology and information security for over 25 years, including in the telecommunications and management consultancy sectors and serving as the Chief Information Security Officer of two large public companies.
The [removed: CDIO] [added: Chief Global Digital & Information Officer] holds an engineering degree and has served in various senior positions in information technology for over 20 years, including serving as Senior Vice President, IT Sales, and Global Chief Information Officer at a public company.
The [added: Group] CEO [added: PMI] has served in various positions in finance and general management at PMI for over 30 years, including as Chief Financial Officer and Chief Operating Officer, and holds a master’s degree in economics.
The [removed: CFO] [added: Group Chief Financial Officer] has over 15 years of experience in finance and management, having held several executive positions in charge of finance, legal affairs information systems and industry administration at various companies.
The [removed: GC] [added: Group Chief Legal Officer] has served at PMI for [removed: 18] [added: 20] years in several positions within the Legal & Compliance department, including as Vice President and Associate General Counsel of various regions, and holds two master’s degrees having studied law, management and finance.
communications or presentations.
Item 2. Properties.
7 rewritten, 2 added, 0 removed, 4 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
At December 31, [removed: 2024,] [added: 2025,] we operated and owned a total of [removed: 51] [added: 50] manufacturing facilities across our segments.
Among them, [removed: 9] [added: 11] factories produced heated tobacco units and [removed: 7] [added: 10] factories produced oral nicotine products.
In [removed: 2024,] [added: 2025,] certain of our facilities each manufactured over 30 billion units (cigarettes and heated tobacco units combined).
Our largest manufacturing facilities, in terms of cigarette and heated tobacco unit volume, are located in Turkey (SSEA, CIS & MEA), Russia (SSEA, CIS & MEA), [added: Poland (Europe),] Indonesia (SSEA, CIS & MEA), [removed: Poland (Europe),] Italy (Europe), Czech Republic [added: (Europe), Lithuania] (Europe) and [removed: Lithuania] [added: Portugal] (Europe).
As part of our global operating model, products manufactured in a particular manufacturing facility are not necessarily distributed in the [removed: operating segment] [added: geographical region] where the facility is located.
We have integrated the production of our heated tobacco units [added: and nicotine pouches] into a number of our existing manufacturing facilities, and we are progressing with our plans to build manufacturing capacity for our smoke-free products.
We believe the properties owned or leased by our subsidiaries are maintained in good condition and are believed to be suitable and adequate for our present [removed: needs.][added: needs in all material respects.]
For additional information related to our manufacturing facilities in Ukraine, see the "War in Ukraine" section of Item 7.
*Management’s Discussion and Analysis of Financial Condition and Results of Operations*.
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
10 rewritten, 10 added, 14 removed, 11 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
At January [removed: 31, 2025,] [added: 30, 2026,] there were approximately [removed: 38,800] [added: 36,500] holders of record of our common stock.
The graph assumes the investment of $100 as of December 31, [removed: 2019,] [added: 2020,] in PMI common stock (at prices quoted on the New York Stock Exchange), and each of the indices as of the market close and reinvestment of dividends on a quarterly basis.
[removed: ][added: ]
| December 31, [removed: 2019] [added: 2020] | | | | | | $100.00 | | | | | | | | | $100.00 | | | | | | $100.00 | | |
As a result of this review, the following companies constitute the PMI Peer Group: Altria Group, Inc., Anheuser-Busch InBev SA/NV, British American Tobacco p.l.c., The Coca-Cola Company, Colgate-Palmolive Co., Diageo plc, Heineken N.V., Imperial Brands PLC, Japan Tobacco Inc., Johnson & Johnson, Kimberly-Clark Corporation, The [removed: Kraft-Heinz] [added: Kraft Heinz] Company, McDonald's Corp., Mondelēz International, Inc., Nestlé S.A., PepsiCo, Inc., The Procter & Gamble Company, Roche Holding AG, and Unilever NV and PLC.
Issuer Purchases of Equity Securities During the Quarter Ended December 31, [removed: 2024][added: 2025]
Our share repurchase activity for each of the three months in the quarter ended December 31, [removed: 2024,] [added: 2025,] was as follows:
| December [removed: 1, 2024 – December] 31, 2024 [removed: (1)] | | | | | | [removed: | | |] [added: $179.10] | | | [removed: $] | [removed: —] | | | | | [removed: —] [added: $109.70] | | | | | | [removed: $] [added: $166.40] | [removed: —] | |
| For the Quarter Ended December 31, [removed: 2024] [added: 2025] | | | | | | [removed: 6,376] [added: 14,621] | | | | | | $ | [removed: 130.09] [added: 158.91] | | | | | | | | | | | | | |
[removed: (2)Shares] [added: (1)Shares] repurchased represent shares tendered to us by employees who vested in restricted and performance share unit awards and used shares to pay all, or a portion of, the related taxes.
| December 31, 2021 | | | | | | $120.80 | | | | | | | | | $114.80 | | | | | | $128.70 | | |
| December 31, 2022 | | | | | | $135.70 | | | | | | | | | $111.20 | | | | | | $105.40 | | |
| December 31, 2023 | | | | | | $133.30 | | | | | | | | | $109.50 | | | | | | $133.10 | | |
| December 31, 2025 | | | | | | $247.10 | | | | | | | | | $128.30 | | | | | | $196.20 | | |
| October 1, 2025 – October 31, 2025 | | | | | | | | | | | | $ | — | | | | | — | | | | | | $ | — | |
| November 1, 2025 – November 30, 2025 | | | | | | | | | | | | $ | — | | | | | — | | | | | | $ | — | |
| December 1, 2025 – December 31, 2025 | | | | | | | | | | | | $ | — | | | | | — | | | | | | $ | — | |
| October 1, 2025 – October 31, 2025 (1) | | | | | | 11,008 | | | | | | $ | 162.08 | | | | | | | | | | | | | |
| November 1, 2025 – November 30, 2025 (1) | | | | | | 2,422 | | | | | | $ | 147.62 | | | | | | | | | | | | | |
| December 1, 2025 – December 31, 2025 (1) | | | | | | 1,191 | | | | | | $ | 152.53 | | | | | | | | | | | | | |
| December 31, 2020 | | | | | | $103.90 | | | | | | | | | $107.00 | | | | | | $118.40 | | |
| December 31, 2021 | | | | | | $125.50 | | | | | | | | | $123.70 | | | | | | $152.40 | | |
| December 31, 2022 | | | | | | $141.00 | | | | | | | | | $119.90 | | | | | | $124.80 | | |
| December 31, 2023 | | | | | | $138.50 | | | | | | | | | $118.00 | | | | | | $157.60 | | |
| December 31, 2024 | | | | | | $186.00 | | | | | | | | | $117.80 | | | | | | $197.00 | | |
| October 1, 2024 – October 31, 2024 (1) | | | | | | | | | | | | $ | — | | | | | — | | | | | | $ | — | |
| November 1, 2024 – November 30, 2024 (1) | | | | | | | | | | | | $ | — | | | | | — | | | | | | $ | — | |
| October 1, 2024 – October 31, 2024 (2) | | | | | | 1,346 | | | | | | $ | 121.24 | | | | | | | | | | | | | |
| November 1, 2024 – November 30, 2024 (2) | | | | | | 4,173 | | | | | | $ | 132.92 | | | | | | | | | | | | | |
| December 1, 2024 – December 31, 2024 (2) | | | | | | 857 | | | | | | $ | 130.20 | | | | | | | | | | | | | |
(1)On June 11, 2021, our Board of Directors authorized a new share repurchase program of up to $7 billion, with target spending of $5 billion to $7 billion over a three-year period that commenced in July 2021.
These share repurchases have been made pursuant to the $7 billion program.
On May 11, 2022, we announced the suspension of our three-year share repurchase program following the recommended public offer to acquire the outstanding shares of Swedish Match from its shareholders.
Our three-year share repurchase program expired on July 21, 2024.
Item 8. Financial Statements and Supplementary Data.
791 rewritten, 345 added, 515 removed, 858 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
| for the years ended December 31, | | | [removed: 2024] [added: 2025] | | | | | | [removed: 2023] [added: 2024] | | | | | | [removed: 2022] [added: 2023] | | |
| Net revenues 1 & 2 (Notes [removed: 6] [added: 5] & [removed: 13)] [added: 11)] | | | $ | [removed: 37,878] [added: 40,648] | | | | | $ | [removed: 35,174] [added: 37,878] | | | | | $ | [removed: 31,762] [added: 35,174] | |
| Cost of sales [removed: (Notes 4 & 5)] | | | [removed: 13,329] [added: 13,366] | | | | | | [removed: 12,893] [added: 13,329] | | | | | | [removed: 11,402] [added: 12,893] | | |
| Gross profit | | | [removed: 24,549] [added: 27,282] | | | | | | [removed: 22,281] [added: 24,549] | | | | | | [removed: 20,360] [added: 22,281] | | |
| Marketing, administration and research costs (Notes 3, 4, [removed: 5, 13] [added: 11] & [removed: 20)] [added: 18)] | | | [removed: 11,147] [added: 12,349] | | | | | | [removed: 10,060] [added: 11,147] | | | | | | [removed: 8,114] [added: 10,060] | | |
| Impairment of goodwill (Note [removed: 5)] [added: 4)] | | | [removed: —] [added: 41] | | | | | | [removed: 665] [added: —] | | | | | | [removed: —] [added: 665] | | |
| Operating income | | | [removed: 13,402] [added: 14,892] | | | | | | [removed: 11,556] [added: 13,402] | | | | | | [removed: 12,246] [added: 11,556] | | |
| Interest expense, net (Note [removed: 15)] [added: 13)] | | | [removed: 1,143] [added: 966] | | | | | | [removed: 1,061] [added: 1,143] | | | | | | [removed: 588] [added: 1,061] | | |
| Pension and other employee benefit costs (Note [removed: 14)] [added: 12)] | | | [removed: 60] [added: 46] | | | | | | [removed: 45] [added: 60] | | | | | | [removed: 24] [added: 45] | | |
| Earnings before income taxes | | | [removed: 12,199 | | | | | | 10,450] [added: $] | [added: 12,199] | | | | | [removed: 11,634] [added: $] | [added: 10,450] | |
| Provision for income taxes (Note [removed: 12)] [added: 10)] | | | [removed: 3,017] [added: 2,737] | | | | | | [removed: 2,339] [added: 3,017] | | | | | | [removed: 2,244] [added: 2,339] | | |
| Impairment related to the RBH equity investment (Note [removed: 6)] [added: 5)] | | | [removed: 2,316] [added: —] | | | | | | [removed: —] [added: 2,316] | | | | | | — | | |
| Equity investments and securities (income)/loss, net | | | [removed: (637)] [added: (705)] | | | | | | [removed: (157)] [added: (637)] | | | | | | [removed: (137)] [added: (157)] | | |
| Net earnings | | | [removed: 7,503] [added: 11,848] | | | | | | [removed: 8,268] [added: 7,503] | | | | | | [removed: 9,527] [added: 8,268] | | |
| Net earnings attributable to noncontrolling interests | | | [removed: 446] [added: 500] | | | | | | [removed: 455] [added: 446] | | | | | | [removed: 479] [added: 455] | | |
| Net earnings attributable to PMI | | | $ | [removed: 7,057] [added: 11,348] | | | | | $ | [removed: 7,813] [added: 7,057] | | | | | $ | [removed: 9,048] [added: 7,813] | |
| Per share data (Note [removed: 11):] [added: 9):] | | | | | | | | | | | | | | | | | |
| Basic earnings per share | | | $ | [removed: 4.53] [added: 7.27] | | | | | $ | [removed: 5.02] [added: 4.53] | | | | | $ | [removed: 5.82] [added: 5.02] | |
| Diluted earnings per share | | | $ | [removed: 4.52] [added: 7.26] | | | | | $ | [removed: 5.02] [added: 4.52] | | | | | $ | [removed: 5.81] [added: 5.02] | |
(1) Includes net revenues from related parties of [removed: $3,876] [added: $4,582] million, [removed: $3,553] [added: $3,876] million and [removed: $3,658] [added: $3,553] million for the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022,] [added: 2023,] respectively
For the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022,] [added: 2023,] excise tax on products was [removed: $51,563] [added: $53,211] million, [removed: $49,404] [added: $51,563] million and [removed: $48,958] [added: $49,404] million, respectively
| for the years ended December 31, | | | [removed: 2024] [added: 2025] | | | | | | [removed: 2023] [added: 2024] | | | | | | [removed: 2022] [added: 2023] | | |
| Net earnings | | | $ | [removed: 7,503] [added: 11,848] | | | | | $ | [removed: 8,268] [added: 7,503] | | | | | $ | [removed: 9,527] [added: 8,268] | |
| Unrealized gains (losses), net of income taxes of [added: $349 in 2025,] $(208) in [removed: 2024,] [added: 2024 and] $156 in 2023 [removed: and $(169) in 2022] | | | [removed: (122)] [added: (1,864)] | | | | | | [removed: (1,643)] [added: (122)] | | | | | | [removed: (1,268)] [added: (1,643)] | | |
| (Gains)/losses transferred to earnings, net of income taxes of [added: $0 in 2025,] $7 in [removed: 2024,] [added: 2024 and] $0 in 2023 [removed: and 2022] (Notes 3, [removed: 17] [added: 15] & [removed: 20)] [added: 18)] | | | [removed: 171] [added: 3] | | | | | | [removed: 12] [added: 171] | | | | | | [removed: —] [added: 12] | | |
| Net gains (losses) and prior service costs, net of income taxes of [added: $(176) in 2025,] $8 in [removed: 2024,] [added: 2024 and] $182 in 2023 [removed: and $(132) in 2022] | | | [removed: (10)] [added: 884] | | | | | | [removed: (861)] [added: (10)] | | | | | | [removed: 843] [added: (861)] | | |
| Amortization of net losses, prior service costs and net transition costs, net of income taxes of [added: $(46) in 2025,] $(36) in [removed: 2024,] [added: 2024 and] $(28) in 2023 [removed: and $(49) in 2022] | | | [removed: 135] [added: 175] | | | | | | [removed: 87] [added: 135] | | | | | | [removed: 217] [added: 87] | | |
| Gains (losses) recognized, net of income taxes of [added: $19 in 2025,] $(88) in [removed: 2024,] [added: 2024 and] $(30) in 2023 [removed: and $(99) in 2022] | | | [removed: 439] [added: (89)] | | | | | | [removed: 195] [added: 439] | | | | | | [removed: 481] [added: 195] | | |
| (Gains) losses transferred to earnings, net of income taxes of [added: $18 in 2025,] $45 in [removed: 2024,] [added: 2024 and] $32 in 2023 [removed: and $35 in 2022] | | | [removed: (213)] [added: (94)] | | | | | | [removed: (220)] [added: (213)] | | | | | | [removed: (219)] [added: (220)] | | |
| Total other comprehensive earnings (losses) | | | [removed: 400] [added: (985)] | | | | | | [removed: (2,430)] [added: 400] | | | | | | [removed: 54] [added: (2,430)] | | |
| Total comprehensive earnings | | | [removed: 7,903] [added: 10,863] | | | | | | [removed: 5,838] [added: 7,903] | | | | | | [removed: 9,581] [added: 5,838] | | |
| Noncontrolling interests | | | [removed: 345] [added: 497] | | | | | | [removed: 281] [added: 345] | | | | | | [removed: 515] [added: 281] | | |
| Comprehensive earnings attributable to PMI | | | $ | [removed: 7,558] [added: 10,366] | | | | | $ | [removed: 5,557] [added: 7,558] | | | | | $ | [removed: 9,066] [added: 5,557] | |
| [removed: at December 31,] | | | [added: | | | | | |] 2024 | | | | | | 2023 | | |
| Cash and cash equivalents | | | $ | [removed: 4,216] [added: 4,872] | | | | | $ | [removed: 3,060] [added: 4,216] | |
| Trade receivables (less allowances of [removed: $47] [added: $23] in [removed: 2024] [added: 2025] and [removed: $79] [added: $47] in [removed: 2023)] [added: 2024)] (1) | | | [removed: 3,789] [added: 4,572] | | | | | | [removed: 3,461] [added: 3,789] | | |
| Other receivables (less allowances of [removed: $22] [added: $24] in [removed: 2024] [added: 2025] and [removed: $35] [added: $22] in [removed: 2023)] [added: 2024)] | | | [removed: 886] [added: 1,238] | | | | | | [removed: 930] [added: 886] | | |
| Leaf tobacco | | | [removed: 2,080] [added: 2,425] | | | | | | [removed: 1,942] [added: 2,080] | | |
| Other raw materials | | | [removed: 2,261] [added: 2,223] | | | | | | [removed: 2,293] [added: 2,261] | | |
| Finished product | | | [removed: 5,112] [added: 6,830] | | | | | | [removed: 6,539] [added: 5,112] | | |
| | | | 11,478 | | | | | | 9,453 | | |
| | | | 19,616 | | | | | | 16,685 | | |
| | | | 8,397 | | | | | | 7,310 | | |
| Other liabilities | | | 2,181 | | | | | | 1,116 | | |
| | | | 25,557 | | | | | | 23,890 | | |
| Losses on sales of businesses (including held-for-sale) (Note 3) | | | 94 | | | | | | 206 | | | | | | — | | | | | |
| Purchases of debt securities | | | (202) | | | | | | (132) | | | | | | — | | | | | |
| Sales and maturities of debt securities | | | 116 | | | | | | — | | | | | | — | | | | | |
| Net earnings | | | | | | | | | | | | | | | 11,348 | | | | | | | | | | | | | | | | | | 500 | | | | | | | | | 11,848 | | | | | |
| Balances, December 31, 2025 | | | $ | — | | | | | $ | 2,453 | | | | | $ | 35,400 | | | | | $ | (12,296) | | | | | $ | (35,551) | | | | | $ | 1,966 | | | | | | | | $ | (8,028) | | | | |
Following the sale of Vectura Group Ltd. on December 31, 2024, PMI updated in January 2025 its segment reporting by including the ongoing Wellness results (previously referred to as Wellness & Healthcare) in the Europe segment.
For further details on the sale of Vectura Group Ltd., see *Note 3.
In addition, PMI renamed its “PMI Duty Free” business to “PMI Global Travel Retail” effective in the first quarter of 2025.
As a result of this change, PMI's segment that includes its duty free business was renamed East Asia, Australia & PMI Global Travel Retail (“EA, AU & PMI GTR”).
As communicated in the fourth quarter of 2025, with PMI's smoke-free business now operating at scale across its regions, including substantial growth from its U.S. business, PMI has implemented an evolved organizational model with two primary business units: International and U.S. The updated organizational structure is designed to enhance PMI's agility and to support its journey to become a smoke-free company under the leadership of Jacek Olczak, Group CEO of PMI.
This change was implemented effective January 1, 2026, and as a result PMI realigned its reportable segments accordingly.
The four geographic segments have been replaced with three new reportable segments: International Smoke-Free, International Combustibles, and U.S. As of the first quarter of 2026, our reporting will reflect these changes.
PMI records provisions in the consolidated financial statements for pending litigation when it is determined that an unfavorable outcome is probable, and the amount of the loss can be reasonably estimated.
Level 2 inputs
The revenue recorded is reported net of excise taxes, consumer and trade promotions, sales returns and includes shipping and handling charges billed to customers.
the time revenue is recognized are accrued.
*Sale of certain other businesses*
During the fourth quarter of 2025, PMI completed the sale of one business and classified as held-for-sale net assets of certain other businesses (disposal group), primarily related to its consumer accessories products acquired as part of the Swedish Match AB acquisition in 2022.
As a result, PMI recorded a pre-tax loss of $94 million, primarily related to the impairment charge to record the net assets held-for-sale at the lower of their carrying value or fair value less costs to sell and the loss on the completed sale, of which $3 million related to the reclassification of currency translation losses from other comprehensive losses for the completed sale.
The estimated fair value of the disposal group less costs to sell was determined using a market approach, based upon the expected net sales proceeds of the disposal group.
As of December 31, 2025 and 2024, the liability related to the indemnity was not material.
The remaining assumed bank loan was repaid in the fourth quarter of 2025.
| Goodwill | | | 510 | | | (5) | | | 505 | | |
| Impairment | | | (41) | | | | | | — | | | — | | | — | | | (41) | | |
| Currency | | | 690 | | | | | | (43) | | | (9) | | | 74 | | | 712 | | |
| Balances, December 31, 2025 | | | $ | 4,779 | | | | | $ | 3,201 | | $ | 461 | | $ | 8,823 | | $ | 17,264 | |
(a) Europe goodwill balance is net of accumulated impairment losses of $556 million at December 31, 2025, and 2024.
These accumulated losses exclude amounts related to businesses which were subsequently sold or reclassified as held-for-sale.
*Background and Basis of Presentation*, following the sale of Vectura Group Ltd. on December 31, 2024, we updated our segment reporting in January 2025 by including the Wellness balance in the Europe segment.
In the second quarter of 2025, PMI finalized the measurement period adjustments related to its acquisition in Egypt of United Tobacco Company (UTC).
| | | | | | | December 31, 2025 | | | | | | | | | | | | December 31, 2024 | | | | | | | | |
| Non-amortizable intangible assets | | | | | | $ | 4,776 | | | | | $ | 4,776 | | | | | $ | 4,446 | | | | | $ | 4,446 | |
Changes in the net carrying amount of intangible assets were as follows:
| (in millions) | | | December 31, 2023 | | | Amortization & Impairment | | | Acquisitions & Divestitures | | | Currency & Other | | | December 31, 2024 | | |
| Amortizable intangible assets: | | | 5,321 | | | (835) | | | (187) | | | 2,582 | | | 6,881 | | |
| | | | 9,453 | | | | | | 10,774 | | |
| | | | 16,685 | | | | | | 17,080 | | |
| | | | 7,310 | | | | | | 7,516 | | |
| Income taxes and other liabilities (Note 12) | | | 1,116 | | | | | | 1,743 | | |
| | | | 23,890 | | | | | | 24,560 | | |
| Loss on sale of Vectura Group (Note 3) | | | 206 | | | | | | — | | | | | | — | | | | | |
| Other acquisitions, net of acquired cash (Note 3) | | | 43 | | | | | | — | | | | | | — | | | | | |
| Repayments under credit facilities related to Swedish Match AB acquisition | | | (3,168) | | | | | | (4,430) | | | | | | (4,000) | | |
| Repurchases of common stock | | | — | | | | | | — | | | | | | (209) | | |
| Balances, January 1, 2022 | | | $ | — | | | | | $ | 2,225 | | | | | $ | 33,082 | | | | | $ | (9,577) | | | | | $ | (35,836) | | | | | $ | 1,898 | | | | | | | | $ | (8,208) | | | | |
| Net earnings | | | | | | | | | | | | | | | 9,048 | | | | | | | | | | | | | | | | | | 479 | | | | | | | | | 9,527 | | | | | |
| Common stock repurchased | | | | | | | | | | | | | | | | | | | | | | | | | | | (199) | | | | | | | | | | | | | | | (199) | | | | | |
| Acquisitions (Note 3) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 160 | | | | | | | | | 160 | | | | | |
On September 17, 2024, PMI announced the execution of a definitive agreement pursuant to which PMI’s direct, wholly-owned subsidiary, Vectura Fertin Pharma Inc., agreed to sell Vectura Group Ltd. (formerly, Vectura Group plc, and hereinafter referred to as “Vectura” or "Vectura Group") to Molex Asia Holdings Ltd. The transaction was completed on December 31, 2024.
Following the combination and the progress in 2023 toward the integration of the Swedish Match business into PMI's existing regional structure, PMI updated in January 2024 its segment reporting by including the former Swedish Match segment results into the four existing geographical segments.
The Wellness and Healthcare ("W&H") segment remained unchanged.
*Segment Reporting* and Note 20.
In an asset acquisition, acquired in-process research and development ("IPR&D") with no alternative future use is charged to expense.
accounted for using the equity method of accounting.
| Goodwill | | | 512 | | |
The purchase price allocation is preliminary and continues to be subject to refinement.
PMI is evaluating the deductibility of goodwill for income tax purposes.
*Swedish Match AB* – On November 11, 2022 (the acquisition date), Philip Morris Holland Holdings B.V. (“PMHH”), a wholly owned subsidiary of PMI, acquired a controlling interest of 85.87% of the total issued shares in Swedish Match AB (“Swedish Match”) and acquired 94.81% of its outstanding shares as of December 31, 2022.
The shares were acquired through acceptances of the tender offer and a series of open market and over-the-counter purchases.
PMI funded the acquisition through cash on-hand and debt proceeds, as described in Note 8.
*Indebtedness.* The aggregate cash paid as of the acquisition date was $14,460 million (or $13,976 million net of cash acquired), which was included in investing activities in the consolidated statements of cash flows for the year ended December 31, 2022.
The cash paid in connection with the additional purchases of the noncontrolling interests after the acquisition date and through December 31, 2022 amounted to $1,495 million and was included in financing activities in the consolidated statements of cash flows for the year ended December 31, 2022.
In accordance with the Swedish Companies Act, PMI subsequently exercised its right to initiate arbitral proceedings to compulsorily redeem the remaining shares for which acceptances were not received and obtained legal title to 100% of the shares in Swedish Match on February 17, 2023.
Cash paid in connection with such legal title, together with an immaterial amount attributable to open market purchases that were executed in December 2022 but settled in January 2023, amounted to $883 million and was included in financing activities in the consolidated statements of cash flows for the year ended December 31, 2023.
While PMI paid the referenced amounts and acquired legal title to the shares, under the Swedish Companies Act the redemption process was not complete until the final redemption price was determined by an arbitral tribunal.
On September 12, 2023, the arbitral tribunal determined the final redemption price to be Swedish krona (SEK) 115.07, unchanged from the SEK 115.07 that PMI paid per share in connection with obtaining legal title to the shares.
This process was completed in the fourth quarter of 2023 when the opportunity to appeal the arbitral tribunal determination ended.
Swedish Match is a market leader in oral nicotine delivery with a significant presence in the United States market.
The acquisition is accelerating PMI’s transformation to become a smoke-free company with a comprehensive global smoke-free portfolio with leadership positions in heat-not-burn and the fastest growing category of oral nicotine.
The table below summarizes the final purchase price allocation for the fair value of assets acquired and liabilities assumed as of the acquisition date:
| Trade receivables | | | | | | | | | 135 | | |
| Inventories | | | | | | | | | 437 | | |
| Other current assets | | | | | | | | | 415 | | |
| Other intangible assets | | | | | | | | | 7,868 | | |
| Other non-current assets | | | | | | | | | 216 | | |
An excerpt. Shown here: 40 of 791 rewritten, 40 of 345 added and 40 of 515 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data. in the FY2025 filing and the FY2024 filing.
Item 9A. Controls and Procedures.
2 rewritten, 0 added, 0 removed, 2 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
PMI carried out an evaluation, with the participation of PMI’s management, including [removed: PMI’s Chief Executive Officer] [added: our Group CEO PMI] and [added: Group] Chief Financial Officer, of the effectiveness of PMI’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report.
Based upon that evaluation, [removed: PMI’s Chief Executive Officer] [added: our Group CEO PMI] and [added: Group] Chief Financial Officer concluded that PMI’s disclosure controls and procedures are effective.
Item 9B. Other Information.
3 rewritten, 0 added, 0 removed, 0 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
On February [removed: 4, 2025, Juan José Daboub] [added: 5, 2026, Dessislava Temperley] informed PMI's board of directors (the “Board”) that [removed: he] [added: she] will not stand for re-election to the Board at our [removed: 2025] [added: 2026] annual meeting of shareholders.
[removed: Dr. Daboub’s] [added: Ms. Temperley's] decision not to stand for re-election to the Board was not a result of any disagreement with the Company.
During the three months ended December 31, [removed: 2024,] [added: 2025,] no director or officer of PMI adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as such terms are defined in Item 408(a) of Regulation S-K.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
1 rewritten, 0 added, 0 removed, 2 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
Except for the information relating to the executive officers set forth in Item 10 and the information relating to equity compensation plans set forth in Item 12, the information called for by Items 10-14 is hereby incorporated by reference to PMI’s definitive proxy statement for use in connection with its annual meeting of stockholders to be held on May [removed: 7, 2025,] [added: 6, 2026,] that will be filed with the SEC on or about March [removed: 27, 2025] [added: 26, 2026] (the “proxy statement”), and, except as indicated therein, made a part hereof.
Item 10. Directors, Executive Officers and Corporate Governance.
21 rewritten, 5 added, 34 removed, 29 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
Information About Our Executive Officers as of February 6, [removed: 2025:][added: 2026:]
| Emmanuel Babeau | | | | | | [added: Group] Chief Financial Officer | | | | | | [removed: 57] [added: 58] | | | | | |
[removed: | Frederic] [added: Mr.] de Wilde [removed: | | | | | |] [added: was appointed as CEO PMI International, effective January 1, 2026, having previously served as] President, South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa [removed: Region | | | | | | 57 | | | | | |][added: Regions since January 2023.]
| Reginaldo Dobrowolski | | | | | | [removed: Vice President and] [added: Group] Controller | | | | | | [removed: 50] [added: 51] | | | | | |
| Stacey Kennedy | | | | | | [removed: President, Americas Region &] CEO [removed: of PMI's] [added: PMI] U.S. [removed: Business] | | | | | | [removed: 52] [added: 53] | | | | | |
Jacek Olczak – Age [removed: 60][added: 61]
Mr. Olczak was appointed as [added: Group CEO PMI, effective January 1, 2026, having previously served as] our Chief Executive Officer [removed: in] [added: since] May 2021.
From January 2018 until May 2021, Mr. Olczak has served as our Chief Operating [removed: Officer, and] [added: Officer and,] from August 2012 until December 31, 2017, he served as our Chief Financial Officer.
Emmanuel Babeau – Age [removed: 57][added: 58]
Mr. Babeau was appointed as [added: Group Chief Financial Officer, effective January 1, 2026, having previously served as] our Chief Financial Officer [removed: in] [added: since] May 2020.
Frederic de Wilde – Age [removed: 57][added: 58]
Reginaldo Dobrowolski – Age [removed: 50][added: 51]
Mr. Dobrowolski was appointed as [removed: our] [added: Group Controller, effective January 1, 2026, having previously served as] Vice President and Controller [removed: in] [added: since] August 2021.
Yann Guérin - Age [removed: 48][added: 49]
[removed: Mr. Guérin was appointed as Senior Vice President and General Counsel in July 2023, having] [added: Prior to that, he] served as Senior Vice President and Global Head of Law and Compliance [removed: for] [added: in] June 2023.
[removed: Previously,] [added: From July 2021 until May 2023,] he served as Vice President and Associate General Counsel, [removed: Corporate from July 2021 to May 2023;] [added: Corporate;] as Vice President and Associate General Counsel, South & Southern Asia from November 2019 [removed: to] [added: until] June 2021; and as Vice President and Associate General Counsel, Middle-East, Africa & Global Duty Free from January 2018 [removed: to] [added: until] October 2019.
[removed: Prior to that, since] [added: Since] joining PMI in 2006, Mr. Guérin held a variety of legal roles across the company’s businesses, regions and functions.
Stacey Kennedy – Age [removed: 52][added: 53]
Ms. Kennedy was appointed as [removed: our] [added: CEO PMI U.S., effective January 1, 2026, having previously served as] President, Americas Region & CEO of PMI's U.S. Business [removed: in] [added: since] January 2023.
[removed: Previously,] [added: Prior to that,] she served as our President, South and Southeast Asia Region from January [removed: 2018.][added: 2018 until January 2023.]
Also refer to *Board Operations and Governance—Committees of the Board*, *Election of Directors—Process for Nominating Directors,* *Election of Directors—Director Nominees*, *Stock Ownership Information* and *Availability of Reports, Other Matters and [removed: 2026] [added: 2027] Annual [removed: Meeting—2026] [added: Meeting—2027] Annual Meeting* sections of the proxy statement.
| Jacek Olczak | | | | | | Group CEO PMI | | | | | | 61 | | | | | |
| Frederic de Wilde | | | | | | CEO PMI International | | | | | | 58 | | | | | |
| Yann Guérin | | | | | | Group Chief Legal Officer | | | | | | 49 | | | | | |
From July 2015 until January 2023, he served as President, European Union Region.
Mr. Guérin was appointed as Group Chief Legal Officer, effective January 1, 2026, having previously served as Senior Vice President and General Counsel since July 2023.
| Jacek Olczak | | | | | | Chief Executive Officer | | | | | | 60 | | | | | |
| Massimo Andolina | | | | | | President, Europe Region | | | | | | 56 | | | | | |
| Werner Barth | | | | | | President, Combustibles Category & Global Combustibles Marketing | | | | | | 60 | | | | | |
| Lars Dahlgren | | | | | | President, Smoke-Free Oral Products & Chief Executive Officer Swedish Match | | | | | | 54 | | | | | |
| Vassilis Gkatzelis | | | | | | President, East Asia, Australia, and PMI Duty Free Region | | | | | | 47 | | | | | |
| Yann Guérin | | | | | | Senior Vice President and General Counsel | | | | | | 48 | | | | | |
| Stefano Volpetti | | | | | | President, Smoke-Free Inhalable Products & Chief Consumer Officer | | | | | | 53 | | | | | |
Massimo Andolina – Age 56
Mr. Andolina was appointed as our President, Europe Region in January 2023, prior to which he served as our Senior Vice President, Operations since January 2018.
He joined PMI in 2008 as Director, Operations Planning, and has held several various roles at PMI, including Vice President, Operations of Latin America & Canada Region from December 2010 to July 2013; Vice President, EU Operations, from August 2013 to June 2016; and Vice President, PMI Transformation from July 2016 to December 2017.
Prior to joining PMI, Mr. Andolina held a variety of international positions in strategic marketing and general management for Tetra Pak International and in operations for R.J. Reynolds International.
Werner Barth – Age 60
Mr. Barth was appointed as our President, Combustibles Category & Global Combustibles Marketing in November 2021.
Mr. Barth joined PMI in 1990 as Marketing Trainee at Philip Morris Germany and throughout his career he progressed through various roles at PMI in marketing, product management, brand supervision and general management.
Prior to his current position, from 2015, Mr. Barth held the role of Senior Vice President, Marketing & Sales, and from 2018, he held the role of Senior Vice President, Commercial.
Lars Dahlgren – Age 54
Mr. Dahlgren was appointed as our President Smoke-Free Oral Products and CEO Swedish Match in January 2023.
Prior to PMI’s acquisition of Swedish Match, he served as President and Chief Executive Officer of Swedish Match since June 2008, and as its Chief Financial Officer and Senior Vice President from July 2004 until June 2008.
Prior to that, from April 2004 to July 2004, he was Acting Chief Financial Officer and Vice President of Finance at Swedish Match.
Mr. Dahlgren joined Swedish Match in 1996 and has been a member of its Group Management Team since 2004.
Mr. de Wilde was appointed as our President, South and Southeast Asia, Commonwealth of Independent States, Middle East and Africa Regions in January 2023, prior to which he served as President, European Union Region from July 2015.
Vassilis Gkatzelis – Age 47
Mr. Gkatzelis was appointed as our President, East Asia, Australia, and PMI Duty Free Region in May 2024.
Previously, he served as our President Director, PT HM Sampoerna Tbk, PMI’s affiliate listed on the Indonesia Stock Exchange, overseeing the smoke-free and combustible business since 2022.
Mr. Gkatzelis joined PMI in 2003 as a management trainee at Philip Morris Greece during the acquisition and integration with Papastratos.
He has held roles of increasing responsibilities in marketing, sales, and general management across markets in Asia, Europe, Middle East & Africa, and in the Global Operations Center in Switzerland, where he served as Director of Commercial Approach Strategy & Deployment.
Since 2014, he assumed roles in general management, including General Manager, Morocco and Managing Director, Egypt & Levant, where he and his team built the smoke-free product category across all markets of the cluster.
Before joining PMI, he worked at L’Oréal.
Stefano Volpetti – Age 53
Mr. Volpetti was appointed as our President Smoke-Free Inhalable Products & Chief Consumer Officer in January 2023, having served as President Smoke-Free Products Category & Chief Consumer Officer from November 2021.
Mr. Volpetti joined PMI in June 2019 as Chief Consumer Officer.
From February 2016 until May 2019, Mr. Volpetti served as the Vice President & Brand Franchise Leader of a multi-functional, global business unit at Procter & Gamble, a multinational consumer goods company.
Mr. Volpetti spent 22 years at Procter & Gamble, progressing through various roles with increasing responsibility locally in Italy and Mexico, and on a regional level for the European market.
Mr. Volpetti also served as Chief Marketing Officer at Luxottica Group S.p.A, an Italian eyewear conglomerate, in 2015.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
2 rewritten, 1 added, 1 removed, 3 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
The number of shares to be issued upon exercise or vesting and the number of shares remaining available for future issuance under PMI’s equity compensation plans at December 31, [removed: 2024,] [added: 2025,] were as follows:
1 Represents [removed: 4,542,654] [added: 4,460,760] shares of common stock that may be issued upon vesting of the restricted share units and [removed: 2,700,320] [added: 2,608,760] shares that may be issued upon vesting of the performance share units if maximum performance targets are achieved for each performance cycle.
| Equity compensation plans approved by stockholders | | | 7,069,520 | | | 1 | | | $ | — | | | | | 17,797,035 | | | | | |
| Equity compensation plans approved by stockholders | | | 7,242,974 | | | 1 | | | $ | — | | | | | 20,045,796 | | | | | |
Item 15. Exhibits and Financial Statement Schedules.
99 rewritten, 15 added, 7 removed, 70 unchanged
Read the full itemFY2025 item · filed February 6, 2026FY2024 item · filed February 6, 2025
| Consolidated Statements of Earnings for the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022] [added: 2023] | | | [removed: [76](#id5122b52f33945ab8feddeff77f46ff7_109)] [added: [66](#i94fca11542804e3f9f5e986269197803_115)] | | |
| Consolidated Statements of Comprehensive Earnings for the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022] [added: 2023] | | | [removed: [77](#id5122b52f33945ab8feddeff77f46ff7_112)] [added: [67](#i94fca11542804e3f9f5e986269197803_118)] | | |
| Consolidated Balance Sheets at December 31, [removed: 2024] [added: 2025] and [removed: 2023] [added: 2024] | | | [removed: [78](#id5122b52f33945ab8feddeff77f46ff7_115)] [added: [68](#i94fca11542804e3f9f5e986269197803_121)] - [removed: [79](#id5122b52f33945ab8feddeff77f46ff7_118)] [added: [69](#i94fca11542804e3f9f5e986269197803_124)] | | |
| Consolidated Statements of Cash Flows for the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022] [added: 2023] | | | [removed: [80](#id5122b52f33945ab8feddeff77f46ff7_121)] [added: [70](#i94fca11542804e3f9f5e986269197803_127)] - [removed: [81](#id5122b52f33945ab8feddeff77f46ff7_124)] [added: [71](#i94fca11542804e3f9f5e986269197803_130)] | | |
| Consolidated Statements of Stockholders’ (Deficit) Equity for the years ended December 31, [removed: 2024, 2023] [added: 2025, 2024] and [removed: 2022] [added: 2023] | | | [removed: [82](#id5122b52f33945ab8feddeff77f46ff7_127)] [added: [72](#i94fca11542804e3f9f5e986269197803_133)] | | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID 1358) | | | [removed: [143](#id5122b52f33945ab8feddeff77f46ff7_202)] [added: [127](#i94fca11542804e3f9f5e986269197803_208)] - [removed: 145] [added: 128] | | |
| Report of Management on Internal Control Over Financial Reporting | | | [removed: [146](#id5122b52f33945ab8feddeff77f46ff7_205)] [added: [129](#i94fca11542804e3f9f5e986269197803_211)] | | |
| 4.3 | | | | | | — | | | | | | [Description of Common [removed: Stock.](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex43_123124xq4.htm)x] [added: Stock.](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex43_123125xq4.htm)x] | | |
| 4.4 | | | | | | — | | | | | | [Description of Debt [removed: Securities.](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex44_123124xq4.htm)x] [added: Securities.](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex44_123125xq4.htm)x] | | |
| [removed: 10.28] [added: 10.29] | | | | | | — | | | | | | [Amendment to the Term Loan Credit Agreement, dated as of November 10, [removed: 2023](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1028.htm) [(incorporated] [added: 2023 (incorporated] by reference to Exhibit 10.28 to the Annual Report on Form [removed: 10-K](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1028.htm) [for] [added: 10-K for] the year ended December 31, [removed: 202](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1028.htm)[3)](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1028.htm)[.](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1028.htm)] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1028.htm)] | | | | | |
| [removed: 10.29] [added: 10.30] | | | | | | — | | | | | | [Purchase Agreement with Altria Client Services LLC, effective October 19, 2022 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed October 20, 2022). ](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000105/purchaseagreement.htm) | | | | | |
| [removed: 10.30] [added: 10.31] | | | | | | — | | | | | | [Extension Agreement, dated as of January 24, 2024 among PMI, the lenders named therein, and Citibank Europe plc, UK Branch (legal successor to Citibank International Limited), as administrative agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed January 24, 2024).](https://www.sec.gov/Archives/edgar/data/1413329/000110465924006244/tm243707d1_ex10-1.htm) | | | | | |
| [removed: 10.31] [added: 10.32] | | | | | | — | | | | | | [Terms Agreement, dated October 30, 2024, among PMI and BBVA Securities Inc., BofA Securities, Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC, Wells Fargo Securities, LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Mizuho Securities USA LLC and UBS Securities LLC, as representatives of the several underwriters named therein (incorporated by reference to Exhibit 1.2 to the Current Report on Form 8-K filed November 1, 2024).](https://www.sec.gov/ix?doc=/Archives/edgar/data/1413329/000110465924113481/tm2426896d4_8k.htm) | | | | | |
| [removed: 10.32] [added: 10.36] | | | | | | — | | | | | | [Philip Morris International Inc. 2017 Performance Incentive Plan, effective May 3, 2017 (incorporated by reference to Exhibit B to the Definitive Proxy Statement filed on March 23, 2017).](https://www.sec.gov/Archives/edgar/data/1413329/000119312517092719/d551682ddef14a.htm#toc551682_47)* | | |
| [removed: 10.33] [added: 10.37] | | | | | | — | | | | | | [Pension Fund of Philip Morris in Switzerland (IC), effective January 1, 2022 (incorporated by reference to Exhibit 10.28 to the Annual Report on Form 10-K for the year ended December 31, 2022).](https://www.sec.gov/Archives/edgar/data/1413329/000141332923000025/pmi-ex1028_123122.htm)* | | |
| [removed: 10.34] [added: 10.38] | | | | | | — | | | | | | [Amended and Restated Pension Fund of Philip Morris in [removed: S](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex1034_123124xq4.htm)[witzerland] [added: Switzerland] (IC), [removed: effective](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex1034_123124xq4.htm) [January] [added: effective January] 1, [removed: 2024](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex1034_123124xq4.htm)[.](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex1034_123124xq4.htm)*x] [added: 2024.](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex1034_123124xq4.htm)*] | | |
| [removed: 10.35] [added: 10.40] | | | | | | — | | | | | | [Summary of Supplemental Pension Plan of Philip Morris in Switzerland, effective December 15, 2022 (incorporated by reference to Exhibit 10.29 to the Annual Report on Form 10-K for the year ended December 31, 2022).](https://www.sec.gov/Archives/edgar/data/1413329/000141332923000025/pmi-ex1029_123122.htm)* | | |
| [removed: 10.36] [added: 10.41] | | | | | | — | | | | | | [Philip Morris International Inc. Amended and Restated Automobile Policy, dated as of September 1, [removed: 2023](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1033.htm) [(incorporated] [added: 2023 (incorporated] by reference to Exhibit 10.33 to the Annual Report on Form 10-K for the year ended December 31, [removed: 202](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1033.htm)[3)](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1033.htm)[.](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1033.htm)*] [added: 2023).](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit1033.htm)*] | | |
| [removed: 10.37] [added: 10.42] | | | | | | — | | | | | | [Form of Restated Employee Grantor Trust Enrollment Agreement (Executive Trust Arrangement) (incorporated by reference to Exhibit 10.18 to the Registration Statement on Form 10 filed February 7, 2008).](https://www.sec.gov/Archives/edgar/data/1413329/000119312508023093/dex1018.htm)* | | |
| [removed: 10.38] [added: 10.43] | | | | | | — | | | | | | [Form of Restated Employee Grantor Trust Enrollment Agreement (Secular Trust Arrangement) (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form 10 filed February 7, 2008).](https://www.sec.gov/Archives/edgar/data/1413329/000119312508023093/dex1019.htm)* | | |
| [removed: 10.39] [added: 10.44] | | | | | | — | | | | | | [Philip Morris International Inc. 2017 Stock Compensation Plan for Non-Employee Directors (as amended and restated as of January 1, 2018) (incorporated by reference to Exhibit 10.26 to the Annual Report on Form 10-K for the year ended December 31, 2017).](https://www.sec.gov/Archives/edgar/data/1413329/000141332918000007/pm-ex1026nedcompensationpl.htm)* | | |
| [removed: 10.40] [added: 10.45] | | | | | | — | | | | | | [Philip Morris International Inc. 2008 Deferred Fee Plan for Non-Employee Directors (incorporated by reference to Exhibit 10.24 the Annual Report on Form 10-K for the year ended December 31, 2020).*](https://www.sec.gov/Archives/edgar/data/1413329/000141332921000007/pm-ex1024_123120xq4.htm) | | |
| [removed: 10.41] [added: 10.46] | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement (as amended) with André Calantzopoulos (incorporated by reference to Exhibit 10.25 to the Annual Report on Form 10-K for the year ended December 31, 2020).](https://www.sec.gov/Archives/edgar/data/1413329/000141332921000007/pm-ex1025_123120xq4.htm) [The Employment Agreement was previously filed as Exhibit 10.22 to the Registration Statement on Form 10 filed February 7, 2008 and is incorporated by reference to this Exhibit [removed: 10.41.](https://www.sec.gov/Archives/edgar/data/1413329/000119312508023093/dex1022.htm)*] [added: 10.46.](https://www.sec.gov/Archives/edgar/data/1413329/000119312508023093/dex1022.htm)*] | | |
| [removed: 10.42] [added: 10.47] | | | | | | — | | | | | | [Supplemental Letter to the Offer Letter with Drago Azinovic, dated December 4, 2008 (incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q for the Quarter ended March 31, 2022)](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000035/pm-ex103_033122xq1.htm)* | | |
| [removed: 10.43] [added: 10.48] | | | | | | — | | | | | | [Employment Agreement with Drago Azinovic, effective August 1, 2012. (incorporated by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q for the Quarter ended March 31, 2022)](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000035/pm-ex104_033122xq1.htm)* | | |
| [removed: 10.44] [added: 10.49] | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement with Drago Azinovic, effective April 1, 2017 (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q for the Quarter ended March 31, 2022)](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000035/pm-ex105_033122xq1.htm)* | | |
| [removed: 10.45] [added: 10.50] | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement with Drago Azinovic, effective January 1, 2018 (incorporated by reference to Exhibit 10.6 to the Quarterly Report on Form 10-Q for the Quarter ended March 31, 2022)](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000035/pm-ex106_033122xq1.htm)* | | |
| [removed: 10.46] [added: 10.51] | | | | | | — | | | | | | [Separation Agreement and Release between Drago Azinovic and Philip Morris Products S.A., effective March 31, 2023 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed March 3, 2023).](https://www.sec.gov/Archives/edgar/data/1413329/000141332923000098/daseparationagreement_final.htm)* | | |
| [removed: 10.47] [added: 10.52] | | | | | | — | | | | | | [Employment Agreement with Jorge Insuasty, effective January 1, 2021 (incorporated by reference to Exhibit 10.7 to the Quarterly Report on Form 10-Q for the Quarter ended March 31, 2022)*](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000035/pm-ex107_033122xq1.htm) | | |
| [removed: 10.48] [added: 10.53] | | | | | | — | | | | | | [Supplemental letter to the Employment Agreement with Jorge Insuasty, effective April 1, 2022 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the Quarter ended June 30, 2022)](https://www.sec.gov/Archives/edgar/data/1413329/000141332922000072/pm-ex101_063022xq2.htm)* | | |
| [removed: 10.49] [added: 10.54] | | | | | | — | | | | | | [Supplemental Letter to Employment Agreement with Marc S. Firestone (incorporated by reference to Exhibit 10.5 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2017).](https://www.sec.gov/Archives/edgar/data/1413329/000141332917000023/a01042017_marcxfirestone.htm) [The Employment Agreement was previously filed as Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and is incorporated by reference to this Exhibit [removed: 10.49.](https://www.sec.gov/Archives/edgar/data/1413329/000141332913000030/pm-ex101_firestoneemployme.htm)*] [added: 10.54.](https://www.sec.gov/Archives/edgar/data/1413329/000141332913000030/pm-ex101_firestoneemployme.htm)*] | | |
| [removed: 10.50] [added: 10.55] | | | | | | — | | | | | | [Employment Agreement with Martin G. King, effective June 1, 2020 (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020).*](https://www.sec.gov/Archives/edgar/data/1413329/000141332920000053/basecontractex1021.htm) | | |
| [removed: 10.51] [added: 10.56] | | | | | | — | | | | | | [Separation Agreement and Release with Martin G. King, dated August 16, 2021 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed August 20, 2021).](https://www.sec.gov/Archives/edgar/data/1413329/000141332921000070/mkseparationagreementandre.htm)* | | |
| [removed: 10.52] [added: 10.57] | | | | | | — | | | | | | [Early Retirement Agreement and Release with Marc S. Firestone, effective November 3, 2020 (incorporated by reference to Exhibit 10.28 to the Annual Report on Form 10-K for the year ended December 31, 2020).*](https://www.sec.gov/Archives/edgar/data/1413329/000141332921000007/pm-ex1028_123120xq4.htm) | | |
| [removed: 10.53] [added: 10.58] | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement (as amended) with Jacek Olczak (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.](https://www.sec.gov/Archives/edgar/data/1413329/000141332919000055/a101jacekolczak1.htm) [The Employment Agreement was previously filed as Exhibit 10.4 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, and is incorporated by reference to this Exhibit [removed: 10.53.](https://www.sec.gov/Archives/edgar/data/1413329/000141332912000007/pmex104063012xq2.htm)*] [added: 10.58.](https://www.sec.gov/Archives/edgar/data/1413329/000141332912000007/pmex104063012xq2.htm)*] | | |
| [removed: 10.54] [added: 10.59] | | | | | | — | | | | | | [Supplemental letter to the Employment Agreement with Jacek Olczak, effective April 1, 2023 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023)](https://www.sec.gov/Archives/edgar/data/1413329/000141332923000176/pm-ex101_063023xq2.htm).* | | |
| [removed: 10.55] [added: 10.61] | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement (as amended) with Miroslaw Zielinski (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2019).](https://www.sec.gov/Archives/edgar/data/1413329/000141332919000055/a102zielinskimiroslaw.htm) [The Employment Agreement was previously filed as Exhibit 10.2 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2013 and is incorporated by reference to this Exhibit [removed: 10.55.](https://www.sec.gov/Archives/edgar/data/1413329/000141332913000030/pm-ex102_zielinskicombined.htm)*] [added: 10.61](https://www.sec.gov/Archives/edgar/data/1413329/000141332913000030/pm-ex102_zielinskicombined.htm)*] | | |
| [removed: 10.56] [added: 10.62] | | | | | | — | | | | | | [Early Retirement and Release Agreement with Miroslaw Zielinski, effective April 30, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed May 1, 2020).*](https://www.sec.gov/Archives/edgar/data/1413329/000141332920000034/mzeragr2020.htm) | | |
| [removed: 10.57] [added: 10.63] | | | | | | — | | | | | | [Employment Agreement with Emmanuel Babeau, effective as of May 1, 2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed March 2, 2020).*](https://www.sec.gov/Archives/edgar/data/1413329/000141332920000016/contractpmpsa-nhfa.htm) | | |
| [removed: 10.58] [added: 10.64] | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement with Emmanuel Babeau, effective February 1, 2024 (incorporated by reference to Exhibit 10.10 to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024).](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000087/pm-ex1010_033123xq1.htm)* | | |
| Notes to Consolidated Financial Statements | | | [73](#i94fca11542804e3f9f5e986269197803_139) - [126](#i94fca11542804e3f9f5e986269197803_205) | | |
| 10.28 | | | | | | — | | | | | | [Amendment and Extension Agreement, dated December 11, 2025, among Philip Morris International Inc., the lenders named therein and Citibank Europe PLC, UK Branch, as facility agent (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed December 11, 2025).](https://www.sec.gov/Archives/edgar/data/1413329/000110465925120310/tm2532876d1_ex10-2.htm) | | | | | |
| 10.33 | | | | | | — | | | | | | [Terms Agreement, dated October 27, 2025, among PMI and BBVA Securities Inc., BofA Securities, Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., Wells Fargo Securities, LLC, Goldman Sachs & Co. LLC, HSBC Securities (USA) Inc. and UBS Securities LLC, as representatives of the several underwriters named therein (incorporated by reference to Exhibit 1.2 to the Current Report on Form 8-K filed October 29, 2025).](https://www.sec.gov/Archives/edgar/data/1413329/000110465925103715/tm2529615d1_ex1-2.htm) | | | | | |
| 10.34 | | | | | | — | | | | | | [Credit Agreement, effective as of January 29, 2025, among PMI, the lenders named therein and Citibank Europe PLC, UK Branch, as facility agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed December 17, 2024).](https://www.sec.gov/Archives/edgar/data/1413329/000110465924129362/tm2430819d1_ex10-1.htm) | | | | | |
| 10.35 | | | | | | — | | | | | | [Credit Agreement, dated December 11, 2025, among Philip Morris International Inc., the lenders named therein, Citibank Europe plc, UK Branch, as facility agent, and Citibank, N.A., as swingline agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on December 11, 2025).](https://www.sec.gov/Archives/edgar/data/1413329/000110465925120310/tm2532876d1_ex10-1.htm) | | | | | |
| 10.39 | | | | | | — | | | | | | [Summary of Amended and Restated Pension Fund of Philip Morris in Switzerland (IC), effective January 1, 2024 (incorporated by reference to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025).](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000094/pm-ex101_033125xq1.htm)* | | |
| 10.60 | | | | | | — | | | | | | [Acknowledgement Letter of Transition to PMI Management S](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1060_123125xq4.htm)[à](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1060_123125xq4.htm)[rl with Jacek Olczak, effective January 1, 2026.](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1060_123125xq4.htm)*x | | |
| 10.65 | | | | | | — | | | | | | [Acknowledgement Letter of Transition to PMI Management S](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1065_123125xq4.htm)[à](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1065_123125xq4.htm)[rl with](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1065_123125xq4.htm) [Emmanuel Babeau](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1065_123125xq4.htm)[, effective January 1, 2026.](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1065_123125xq4.htm)*x | | |
| 10.72 | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement with Stefano Volpetti, dated February 27, 2025](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000094/pm-ex103_033125xq1.htm) [(incorporated by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q for the quarter ended Mar](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000094/pm-ex103_033125xq1.htm)[ch 31, 2025).](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000094/pm-ex103_033125xq1.htm)* | | |
| 10.73 | | | | | | — | | | | | | [Acknowledgement Letter of Transition to PMI Global Services Unit Sàrl with Stefano Volpetti, effective January 1, 2026.](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1073_123125xq4.htm)*x | | |
| 10.81 | | | | | | — | | | | | | [Supplemental Letter to the Employment Agreement with Stacey Kennedy, dated June 27, 2025 (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025).](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000150/pm-ex101_063025xq2.htm)* | | |
| 10.82 | | | | | | — | | | | | | [Supplemental letter to the Employment](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1082_123125xq4.htm) [Agreement](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1082_123125xq4.htm) [with](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1082_123125xq4.htm) [S](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1082_123125xq4.htm)[tacey Kennedy](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1082_123125xq4.htm)[, effective January 1, 2026](https://www.sec.gov/Archives/edgar/data/1413329/000162828026005939/pm-ex1082_123125xq4.htm).*x | | |
| 10.94 | | | | | | — | | | | | | [Employment Agreement with Frederic de Wilde, effective January 1, 2026 (incorporated by reference to Exhibit 10.1 to the Current Report filed on November 4, 2025).*](https://www.sec.gov/Archives/edgar/data/1413329/000162828025048526/exhibit101.htm) | | |
| | | | (Jacek Olczak Group CEO PMI) | | |
| /s/ JACEK OLCZAK | | | Group CEO PMI and Director | | | February 6, 2026 | | |
| Notes to Consolidated Financial Statements | | | [83](#id5122b52f33945ab8feddeff77f46ff7_133) - [142](#id5122b52f33945ab8feddeff77f46ff7_199) | | |
| 21 | | | | | | — | | | | | | [Subsidiaries of Philip Morris International Inc.](https://www.sec.gov/Archives/edgar/data/1413329/000141332925000013/pm-ex21_123124xq4.htm)x | | |
| 97 | | | | | | — | | | | | | [Philip Morris International Inc. Policy For Recovery of Erroneously Awarded Incentive Compensation, effective October 2, 2023, and Form of Acknowledgment and Agreement (incorporated by reference to Exhibit 97 to the Annual Report on Form 10-K for the year ended December 31, 2023).](https://www.sec.gov/Archives/edgar/data/1413329/000141332924000013/exhibit97.htm)x | | |
| | | | (Jacek Olczak Chief Executive Officer) | | |
| /s/ JACEK OLCZAK | | | Chief Executive Officer and Director | | | February 6, 2025 | | |
| /s/ DR. JUAN JOSÉ DABOUB | | | Director | | | February 6, 2025 | | |
| (Juan José Daboub) | | | | | | | | |
An excerpt. Shown here: 40 of 99 rewritten, all 15 added and all 7 removed. The counts are complete. For every sentence, read Item 15. Exhibits and Financial Statement Schedules. in the FY2025 filing and the FY2024 filing.